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ABBREVIATIONS 
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FSH   Follicle-stimulating hormone 
FT   Filled teeth 
GCF   Gingival crevicular fluid 
HERS   The Heart and Estrogen/progestin Replacement Study 
HT   Hormone therapy 
HRT   Hormone replacement therapy 
IDF   International Dental Federation 
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K   Potassium 
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MMP   Matrix metalloproteinase 
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MWS   Million Women Study 
Na    Sodium 
NETA   Norethisterone acetate 
NH3   Ammonia 
Ns.   Not significant 
OR   Odds ratio 
P   Probability value 
PCR   Polymerase chain reaction 
P.g.   Porphyromonas gingivalis 
P.i.   Prevotella intermedia 
PM   Sensation of painful mouth 
P.n.   Prevotella nigrescens 
PT   Progestagen-only treatment 
PTG   Panoramic tomography of the jaws 
SD   Standard deviation 
SE   Standard error 
SERM   Selective estrogen-receptor modulators 
RR   Risk ratio 
T.f.   Tannerella forsythia (previously Bacteroides forsythus) 
WHI   Women´s Health Initiative Study 
WHO   World Health Organization 
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DEFINITIONS 
 
Below are listed some brief definitions for terms that are used in this thesis. 
 
Sex steroid hormones  
Female sex hormones are estrogen and progesterone. They are responsible for physiological 
changes in the different stages of a woman’s life, and are feminizing in their action. The ovaries 
secrete estrogens, small amounts of androgens and progesterone. During pregnancy progesterone is 
responsible for preparing the uterus for the pregnancy (Ganong 1989). 
Male sex hormones, generically known as androgens (testosterone, androstenedione, 
dehydroepiandrosterone (DHEA)), are responsible for masculinization. The testes secrete large 
amount of androgens, mainly testosterone, but they also secrete small amounts of estrogens. 
Androgens are also secreted from the adrenal cortex in both sexes (Ganong 1989).  
Estrogens 
 Steroidal estrogens are a group of steroid compounds. The main naturally occurring  
estrogens in women are estrone (E1; after menopause, estrone levels increase, possibly 
due to increased metabolism of androstenedione to estrone), estradiol (E2;  the primary 
estrogen from menarche to menopause) and  estriol (E3; produced during pregnancy by 
the placenta). 
Non-steroidal estrogens are compounds which possess estrogenic activity, eg. 
phytoestrogens and xenoestrogens (Kuhl 2005). 
Progestagens (progestogens, gestagens) are a group of naturally occurring (eg. progesterone) as 
well as synthetic (progestins) hormones having a pregnane skeleton. Progestagens are precursors of 
other steroids (Kuhl 2005). 
Dental caries 
Dental caries is a disease process involving progressive, focal demineralization of dental hard 
tissues by organic acids derived from bacterial fermentation of dietary carbohydrates, especially 
refined sugars (Featherstone 2000). 
Periodontal diseases 
Plaque-induced periodontal diseases are divided into two general categories based on whether 
attachment loss has occurred or not (American Academy of Periodontology 2003).  
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Gingivitis: 
Periodontal disease is categorized as gingivitis based on the presence of gingival inflammation 
without a loss of connective tissue attachment and where the junctional epithelium remains at its 
original level and attached to the tooth (Armitage 1995; Beck & Arbes Jr 2006). 
Periodontitis:  
Periodontal disease is categorized as periodontitis in situations where there is gingival inflammation 
at sites where there has been pathological detachment of collagen fibers from cementum and the 
junctional epithelium has migrated apically (Armitage 1995). In addition to these inflammatory 
events, which are associated with connective tissue attachment loss, the resorption of coronal 
portions of tooth-supporting alveolar bone occurs (Armitage 1995; American Academy of 
Periodontology 2003). 
Indices 
Different indices have been developed to be used for quantifying the amount and severity of 
different oral diseases or conditions in individuals or populations. Some indices are mainly used in 
clinical practice, while other indices are used in epidemiological surveys (Lindhe et al. 2006).  
Dental indices 
 DMFT–index 
The dental caries index, DMF-index, describes the prevalence of dental caries in an individual and 
is obtained by calculating the number of decayed (D), missing (M) and filled (F) teeth. Originally, 
the DMF-index was developed to describe the dental status and need for treatment of elementary 
school children, but the World Health Organization (WHO) has standardized the use of the DMF-
index for oral health surveys for adults and elderly people as well (Larmas 2010).   
Periodontal indices 
CPITN-index 
International Dental Federation (IDF) and WHO jointly developed the Community Periodontal 
Index of Treatment Needs (CPITN) index system (WHO 1978). The CPITN index places each 
subject in a category representing the most severe finding in the mouth. CPITN codes 1 and 2 
indicate gingivitis and scores 3 and 4 (periodontal pockets ≥4mm) indicate periodontitis. The need 
for periodontal treatment is classified in one of four treatment needs categories based on the highest 
CPITN code. Those with codes 1 to 2 require no treatment or only require improvement in their 
personal oral hygiene, whereas those with codes 3 to 4 require scaling and root planning along with 
instructions for improving oral hygiene (Ainamo et al. 1982). 
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ABSTRACT 
 
Unpleasant symptoms connected to menopause are treated with hormone therapy (HT). HT is 
widely used to relieve those symptoms in order to increase the well-being of the women treated. HT 
is also used to prevent age-related diseases such as cardiovascular diseases and osteoporosis. The 
benefits as well as side-effects of HT are well documented. Oral discomfort is found in many 
menopausal women in addition to general climacteric complaints. The principal peri- and 
postmenopausal oral symptoms are dry mouth, sensation of painful mouth (PM) due to various 
causes and less frequently burning mouth syndrome (BMS). BMS is also known as glossodynia, 
since the tongue is most frequently affected. BMS is characterized by burning oral mucosal pain 
without any visible signs of mucosal pathology. The pain also does not follow the anatomy of 
peripheral nerves.  
 
Profile studies on HT users have indicated that these women are more health-conscious than non-
users. Therefore, the hypothesis of the present study was based on the idea that women who had 
chosen to take HT in the first place were those who also had better oral health and health habits in 
general. 
 
A questionnaire study of 3173 women of menopausal age (50-58 years old) was done to investigate 
the prevalence of self-assessed sensations of PM and dry mouth (DM) or xerostomia. Xerostomia is 
the medical term for the subjective complaint of DM. Special attention was paid to the association 
between HT and oral symptoms. Of those women participating in the questionnaire study, a random 
sample of 400 (200 using, 200 not using HT) was then examined clinically in a two-year follow-up 
study. Dental and periodontal status was recorded according to WHO methods using DMFT and 
CPITN indices, and unstimulated and stimulated saliva flows were measured. Salivary total protein, 
albumin and immunoglobulin concentrations as well as selected periodontal micro-organisms were 
analysed. Panoramic tomography of the jaws was taken at baseline and at the follow-up. The 
patients also filled in a structured questionnaire on their systemic health, medication and health 
habits. The results were analysed statistically between and within the groups.  
 
According to our questionnaire study there was no significant difference in the occurrence of self- 
assessed PM or DM between the HT users and non-users. Climacteric symptoms were reported by 
24% (n=761) of the total sample. According to logistic regression analyses, climacteric complaints 
significantly correlated with the occurrence of PM (p=0.000) and DM (p=0.000) irrespective of the 
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use of HT, indicating that PM and DM are associated with climacteric symptoms in general. In the 
clinical study the DMFT index was 20.1 ± 4.3 in the HT users at baseline. There was no difference 
in DMFT index values at follow up, and there was also no difference between HT users and non-
users in this index. The number of filled teeth (FT) showed a significant (p<0.05) increase in the HT 
group at follow-up, however. This result was cautiously interpreted as indicating that women using 
HT were more active for seeking dental treatment than non HT users. Periodontitis (at least one 
sector having a score of 3 in the CPITN index) was diagnosed in 79% of HT users at baseline and in 
71% at the follow-up. The values for non-HT users were 80% vs. 76%, respectively (Ns.). Severe 
periodontits (CPITN score of 4) is diagnosed when there are at least one gingival pocket ≥ 6mm 
deep. The mean numbers of ≥ 6 mm deep periodontal pockets were 0.9 ± 1.7 at baseline vs. 1.1 ± 
2.1 two years later in the HT group, and 1.0 ± 1.7 vs. 1.2 ± 1.9, respectively, in the non-HT group. 
In a large Finnish national health survey, the prevalence of peridontitis of women of this age group 
was lower, but the prevalence of severe periodontitis seemed to be higher than in our study.  
 
No difference was found between the groups in the prevalence of the periodontal bacteria studied. 
Salivary analyses showed that albumin, IgG and IgM concentrations decreased in the HT group 
during the 2-year follow up (p<0.05), possibly indicating an improvement in epithelial integrity. No 
other differences were seen in any other salivary parameters between or within the groups.  
 
In conclusion, the present findings showed that 50 to 58 year old women living in Helsinki have 
fairly good oral and dental health. According to a questionnaire the occurrence of PM and DM 
seemed to be associated with climacteric symptoms in general, and the use of HT did not affect the 
oral symptoms studied. This result did not support our original study hypothesis. More data and a 
longer follow-up period are needed to determine the long-term effects of HT on oral and dental 
health, however. 
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2. INTRODUCTION 
 
In a woman`s life at middle age, during the climacteric process, circulating sex hormone levels 
change and this understandably results in some clinical effects, i.e. climacteric symptoms, which 
also affect the quality of life (Speroff & Fritz 2005; Jalava-Broman et al. 2008; Kase 2009). 
Therefore in the climacterium and post-climacterium, hormone therapy (HT) which consists of 
administration of estrogens, progestins, and estrogen-progestin combinations, is used to alleviate 
climacteric complaints and also to prevent age-related diseases (te Velde & Van Leusden 1994; 
Stefanick 2005; Nelson 2008).  
 
Oral health means much more than healthy teeth, and the relationship between oral and general 
health has been shown (WHO 2010). The majority of pain and discomfort in the oral cavity is due 
to diseases of the mouth. However, there are situations where oral symptoms are a consequence of 
systemic diseases or systemic alterations in physiological conditions.  
 
Oral discomfort is found in many menopausal women. The principal peri- and postmenopausal oral 
symptoms are dry mouth, sensation of painful mouth (PM) of several causes, and less frequently 
burning mouth syndrome (BMS).   
 
PM has been associated with reduced salivary flow rate (Lamey & Lamb 1988) and the presence of 
removable dentures (Main & Basker 1983). Mandibular dysfunction (Lamey & Lamb 1988) and 
also diffuse gingival atrophy or oral ulcerations can be present with oral dryness, causing PM 
(Forabosco et al. 1992). Other possible causative factors of PM are oral candidosis (Samaranayake 
et al. 1989; Wardrop et al. 1989), pernicious anemia (Hjørtin-Hansen & Bertram 1986), and some 
nutritional deficiencies (Lamey et al. 1986).  
 
BMS is defined as a chronic condition characterized by a burning sensation of the oral mucosa, with 
or without dysgeusia (the distortion of the sense of taste) and xerostomia, in the setting of no 
identifiable clinical lesions, laboratory abnormalities, or causative systemic disease (Torgerson 
2010; Zakrewska et al. 2005). This chronic pain is described by patients as a burning or stinging 
sensation of the tongue, lips or other oral mucosal surfaces (Zakrewska 1995; Zakrewska et al. 
2005; Hagqvist et al. 2009; Ni Riordain et al. 2010). The intensity of the pain is moderate to severe 
and it generally occurs bilaterally (Woda & Pionchon 1999). The etiology of the BMS is, however, 
not known, although lately neuronal mechanisms have been suggested to be involved in its 
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occurrence (Jääskeläinen et al. 1997; Forssell et al. 2002). Nevertheless comprehensive data on 
BMS prevalence are lacking. 
 
Salivary gland hypofunction has been divided into three different entities: xerostomia (a subjective 
sensation of dry mouth), hyposalivation (decresed saliva flow rate) and altered saliva composition 
(determined by laboratory testing) (Nederfors 2000). However, there is no global consensus 
concerning the terminology associated with dry mouth and therefore there can also be some 
confusion in clinical practice as well as in interpretation of different published data eg. xerostomia 
and hyposalivation are quite commonly used as synonyms. Women seem to suffer from xerostomia 
or hyposalivation more often than men (Sreebny & Valdini 1988; Nederfors et al. 1997). A recent 
study shows that patients with xerostomia display varying degrees of discomfort related to the 
quality of life depending on the etiology of xerostomia (Cho et al. 2010). The prevalence of 
xerostomia in the population varies with wide range (Nederfors 2000). Sex-related variations in 
salivary flow rates are well documented. In a Finnish study a higher flow rate was found in men 
than in women and a higher flow rate in women of premenopausal than of postmenopausal age 
(Parvinen 1984). A study from the USA did not find any differences in flow rates between 
premenopausal and menopausal women (Ship et al. 1991b).  The effect of hormonal changes related 
to menopause on salivary secretion or composition is not well established. A reduced salivary flow 
rate has been suggested to cause oral symptoms during menopause. Altered saliva composition is 
not analysed routinely in clinical practise, and there are no prevalence data available to show altered 
saliva compositions in menopause. However, the importance of changes in salivary protein 
composition should not be underestimated (Nederfors 2000). 
 
Dental caries and periodontal diseases have historically been considered the most important global 
oral health burdens (WHO 2010). Both dental caries and periodontal diseases are the result of the 
initiation and progression of multiple interrelated processes in which oral bacteria are one 
prominent factor (Thylstrup & Fejerskov 1994; Kinane et al. 2006). Host response and also oral 
hygiene habits are involved in the progression of both diseases. Hormonal changes as seen during 
and after menopause have been associated with osteoporosis but there is a lack of studies linking 
menopause or an estrogen-deficient state to a higher susceptibility to periodontal disease (Kinane et 
al. 2006). Also there are hardly any data on dental health at menopause (Meurman et al. 2009).  
 
Before the HERS and WHI randomized trials demonstrated that the use of HT in healthy and 
asymptomatic postmenopausal women did not have overall health benefits that had been assumed 
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earlier, it seemed that women using HT tended to have healthier lifestyles than non-users 
(Hemminki et al. 1993; Matthews et al. 1996). Therefore we hypothesized that HT users would also 
be more interested in taking care of their oral health. The present series of studies (I, II III and IV) 
were conducted in order to evaluate the oral health of perimenopausal and early postmenopausal 
women with respect to the use of HT. 
.
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3. REVIEW OF THE LITERATURE 
 
3.1 Oral health 
According to the policy of the WHO Oral Health Programme, oral health is integral and essential to 
general health. A major theme of the CAPP-report (http://www.whocollab.od.mah.se/index.html) is 
that oral health means much more than healthy teeth. WHO defines oral health as follows: “Oral 
health implies being free of chronic oro-facial pain, oral and pharyngeal (throat) cancer, oral tissue 
lesions, birth defects such as cleft lip and palate, and other diseases and disorders that affect the 
oral, dental and craniofacial tissues, collectively known as the craniofacial complex” (Petersen 
2003; WHO 2010). We often take the function of these oral tissues for granted, although 
dysfunction of any of these tissues destabilizes our well being. The major functions of these tissues 
are to allow humans to speak, smile, smell, taste, touch, chew, swallow and cry out in pain. Humans 
also use oral tissues to convey their feelings and emotions through facial expressions. In addition, 
oral tissues provide protection against microbial infections and environmental insults (WHO 2010).   
 
Dental caries and periodontal diseases are considered the most important global oral health threats, 
and losing the teeth is still seen by many people as a natural consequence of ageing (Petersen 2003).  
However, according to WHO reports there has been a positive trend, as tooth loss among adults has 
decreased in recent years. The distribution and severity of oral diseases and unfortunately the access 
to oral health services vary markedly in different parts of the world and even within the same 
country and region (WHO 2002b; WHO 2010).   
 
3.2 Oral mucosa 
The mouth or oral cavity is situated at the beginning of the gastrointestinal tract and it is a complex 
organ with various soft and hard tissue anatomical structures. The condition of the oral cavity can 
be seen as a reflection
 
of the general health of the individual. Changes due to diseases, such as 
diabetes
 
or vitamin deficiency, or the local effects of long-term tobacco
 
or alcohol use, are seen as 
alterations in the oral mucosa (Squier & Kremer 2001).   
 
The major role of the oral mucosa is to protect the underlying structures from mechanical damage 
and from the entry of some microorganisms and toxic materials that may present in the oral cavity 
(Squier & Kremer 2001). The soft tissues of the human oral cavity and esophagus are
 
covered by a 
stratified squamous epithelium. The oral mucosa is tightly attached to the underlying collagenous 
connective tissue, called lamina propria (Squier & Kremer 2001). In the oral cavity, mucosal 
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regions differ from each other in their thickness, form, and state of epithelial maturation (Ten Cate 
1994). In those regions that are subject to mechanical forces and associated with mastication
 
(i.e., 
the gingiva and hard palate), the mucosa is covered by a keratinizing
 
epithelium.
 
In some regions of 
the oral
 
cavity, aging causes slight thinning of the epithelium, with concomitant flattening of the 
epithelial-connective tissue interface (Williams & Cruchley 1994). In female patients aging has also 
been shown to decrease the permeability to water of the mucosa of the floor of the mouth (Hill 
1994). Oral buccal epithelia and vaginal epithelia are microscopically similar. Thompson et al. 
(2001) observed that the patterns of surface keratinization and the distribution and appearance of the 
lipid lamellae in the intercellular spaces were similar in vaginal and buccal epithelial samples of 
postmenopausal women. The lipid composition of the two epithelia was similar, except for the 
cholesterol esters and glycosylceramides, which were more abundant in buccal epithelium. The 
response of oral epithelia to hormones and HT is not clear. However, in an earlier study Croley and 
Miers (1978) found that buccal smears of those patients with high estrogen levels had an increased 
number of superficial and keratinized epithelial cells, while those with higher progesterone levels 
had an increased number of intermediate epithelial cells and a decrease in the number of 
keratanized cells.  
Consequently, changes like those seen in studies on vaginal micro-organisms might also be seen in 
the mouth microbiota. However, the oral lactobacilli strains differ from those in vaginal microbiota 
(Witkin et al. 2007). Postmenopausal women have a relative depletion of vaginal lactobacilli and an 
increase in vaginal E. coli compared with premenopausal women (Pabich et al. 2003). For example, 
it has been shown that HT restores the lactobacilli vaginal flora associated with a protective effect 
against urogenital infections (Devillard et al. 2004). Further, oral estriol was found to significantly 
increase lactobacilli in postmenopausal women with symptoms of vaginitis (Yoshimura & Okamura 
2001). Whether corresponding changes are seen in oral microbiota after starting HT is not yet 
known. 
 
3.3 Oral symptoms 
According to the literature and clinical practice, pain and discomfort in the oral cavity are often due 
to local etiologic factors or are consequences of some systemic diseases, or side effect of 
medication. Oral discomfort is found in many menopausal women. Oral discomfort consists of 
various complaints including the sensation of DM, sensation of PM, changes in taste perception, 
and in some cases burning BMS (Ben-Aryeh et al. 1996).  
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3.3.1 Sensation of painful mouth (PM) and burning mouth syndrome (BMS) 
Many menopausal women suffer from oral discomfort. DM and PM are prevalent in women of 
menopausal age. Also, but less frequently, BMS is diagnosed. It is important to distinguish between 
the terms PM and BMS as they represent two different symptoms or syndromes. However, until 
recently there has not been consensus concerning the definition of PM and BMS. Therefore there 
can be confusion in interpreting different data.  
 
Recently Cho et al. (2010) reported that 67% of patients with xerostomia also had the sensation of 
PM and 57% had altered taste sensation as a xerostomia-associated complaint. PM has also been 
found to be associated a with reduced salivary flow rate (Lamey & Lamb 1988). Various denture 
flaws have been considered to be one of the primary factors causing sensation of burning in the 
mouth or PM (Main & Basker 1983) and mandibular dysfunction was found in 30 out of 150 PM 
patients in a study by Lamey & Lamb (1988). Diffuse gingival atrophy and oral ulcerations can be 
present with oral dryness and also cause PM (Forabosco et al. 1992). Other possible causative 
factors of PM are oral candidosis (Samaranayake et al. 1989; Wardrop et al. 1989), and systemic 
factors such as pernicious anemia (Hjørtin-Hansen & Bertram 1986), and other vitamin B-
deficiencies (Lamey et al. 1986).  
 
BMS is a chronic condition in which there is a burning sensation in the oral cavity. The main 
clinical feature of BMS is burning pain. In addition, altered taste sensations and DM are reported by 
these patients. The pain is described using terms such as burning, stinging, tickling or sticking 
sensation (Grushka 1987; Bergdahl & Bergdahl 1999; Tammiala-Salonen et al. 1993). This pain can 
be localized just to the tongue and/or lips but the pain can also involve the whole of the oral cavity 
and in most patients it occurs bilaterally (Grushka 1987; Bergdahl & Bergdahl 1999; Zakrewska 
2005). In most cases the burning pain has continued for many months and the intensity of pain tends 
to increase towards the end of the day. The diagnosis of BMS can be made when the oral mucosa is 
normal on clinical examination and there are no identifiable oral lesions or laboratory abnormalities 
(Lamey & Lamb 1988; Lamey & Lewis 1989; Zakrewska et al. 2005).  
 
The prevalence of BMS has been reported to be 2.6-11% in different groups of people (Basker et al. 
1978). According to a prevalence study in Sweden by Bergdahl & Bergdahl (1999), BMS affects 
3.7% of the general population, and is more common in women (5.5%) than in men (1.6%). In their 
study this difference between genders was particularly seen after menopause in women.  In the 
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Finnish adult population the prevalence of BMS was found to be between 1-15%, depending on the 
criteria for diagnosis (Tammiala-Salonen et al. 1993).  
 
Reviews have collected numerous etiological factors that have been proposed to be involved in 
BMS (Ship et al. 1995; Cibirka et al. 1997; Abetz & Savage 2009; López-Jornet et al. 2010). Still, 
thus far, according to Zakrewska (1995), the etiology of BMS remains an enigma. Pathogenic 
mechanisms, including the possible neuropathic origin, have recently been suggested as possible 
factors underlying BMS (Forssell et al. 2002; Zakrewska et al. 2005; Maltsman-Tseikhin et al. 
2007). In a small Finnish study by Jääskeläinen et al. (1997), an abnormal blink reflex was found in 
chronic BMS patients. The presence of taste anomalies reported in BMS patients suggests 
abnormalities in an interaction between the taste perception and the nociceptive mechanism in the 
central nervous system (López-Jornet et al. 2010). 
 
Antidepressants (Loldrup et al. 1989; Tammiala-Salonen & Forssell 1999), cognitive behavioral 
therapy (Bergdahl et al. 1995), analgesic mouthwash (Sardella et al. 1999), HT in postmenopausal 
women (Pisanty et al. 1975), antioxidants (Femiano et al. 2000; Femiano et al. 2004), and recently 
also acupuncture (Scardina et al. 2010) have been suggested as a treatments in the management of 
BMS patients. However, there are so far no standard treatment protocols for management of this 
disorder (Zakrewska et al. 2005). 
Interestingly, like BMS with its unsolved etiology and difficulties in management of the symptom, 
vulvodynia is a chronic idiopathic pain syndrome with unknown etiology in vulva (Lotery et al. 
2004; Paavonen 2006). Based of some recent case reports, BMS and vulvodynia may share a 
common cause (Gaitonde et al. 2002; Petruzzi et al. 2007; Sivelo & Rodrigues Nuñez 2010). It is 
not known how common “glossovulvodynia” is eg. that patients seldom report genital symptoms to 
the dentist. The symptoms described by the patients suffering of vulvodynia (burning, stinging, 
rawness or stabbing) (Paavonen 1995), mimic the specific symptoms described by BMS patients. 
Vulvodynia has been treated with using drugs effective against chronic neuropathic pain, or with 
cognitive-behavioral therapy, electromyographic biofeedback, and in some cases with 
vestibulectomy (Bergeron et al. 2001). These selected treatments suggest that, as has been 
proposed, this symptom is of neuropathic origin. However, management of vulvodynia remains 
poor and, like BMS, more studies on its treatment are needed according the treatment of vulvodynia 
(Paavonen 2006), as well as of BMS. However, in contrast to BMS, all adult female age groups 
suffer equally from vulvodynia.   
  
20 
 
3.3.2 Sensation of dry mouth (xerostomia) 
The sensation of DM or xerostomia is defined as a subjective sensation of dryness in the mouth 
(Visvanathan & Nix 2010). Xerostomia is a major complaint for many elderly individuals (Wardrop 
et al. 1989; Närhi et al. 1999; Meurman & Rantonen 1994; Nederfors 2000).  However, there is no 
convincing evidence that age alone is a significant cause of xerostomia (Eveson 2008). The 
prevalence of xerostomia is difficult to determine. According to a review article by Orellana et al. 
(2006), the prevalence of self-reported sensations of DM vary between 0.9% and 64.8%. Prevalence 
studies of xerostomia are difficult because of the heterogeneity of the patients. Also there are no 
standardized questions questions for diagnosing xerostomia. Xerostomia has various causes, and 
this symptom is often associated with an unpleasant feeling and other symptoms in the mouth and 
throat (Nederfors 2000; Thelin et al. 2008; CHO et al. 2010).  As there is no doubt that xerostomia 
impairs the quality of life and also causes oral complications, it is important in clinical practice to 
recognize and distinguish between patients with subjective complaints and those who have evidence 
of salivary hypofunction or who are suspected of having some disease, in order to manage these 
conditions appropriately (Napenas et al. 2009).  
 
3.4 Dental health 
As stated by the WHO (2002b), a healthy oral unit consists of a functional, painless and infection-
free oral cavity. Dental caries is a major oral health problem in 60-90% of schoolchildren 
worldwide, and it affects the majority of adults in most industrialized countries (Petersen 2003; 
WHO 2010). National data of the prevalence of dental caries are collected for 12-year-olds as part 
of the surveillance programme of WHO's Department of Noncommunicable Diseases, but there is 
no organized programme for the collection of national data on the oral health of older adults (WHO 
2002a). In a large Finnish population study on adults, at least one decayed tooth with caries was 
detected in 32% of males and in 20% of women (Kansanterveyslaitos 2004). 
 
3.5 Periodontal health 
Periodontium is comprised of gingiva, periodontal ligament, root cementum, and alveolar bone. The 
main function of the periodontium is to attach the tooth to the bone tissue of the jaws and maintain 
the integrity of the surface of the masticatory mucosa of the oral cavity and protect the underlying 
tissues of the periodontium (Lindhe et al. 2006). Periodontal diseases are defined as a group of 
bacterial infectious and inflammatory diseases that result in the destruction of tooth-supporting 
tissue, and may eventually cause tooth and alveolar bone loss (Mealey & Rethman 2003). The 
results from population-based studies have shown that the pathogenesis and severity of periodontitis 
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are dependent on the presence of bacterial plaque and also on the susceptibility of the host 
(Offenbacher 1996; American Academy of Periodontology 2002) as well as on environmental and 
genetic factors (Kinane et al. 2006). Dental plaque can be defined as the soft deposits that form the 
biofilm adhering to the tooth surface and other hard surfaces in the oral cavity (Bowen 1976). The 
pathogenesis of plaque which is associated with gingivitis is due to bacterial accumulations 
(biofilms) on the surface of the teeth close to the gingiva (Haffajee & Socransky 1994). This 
biofilm is known to be resistant to normal host responses, and may initiate vascular changes in the 
gingival tissues, causing migration of polymorphonuclear leukocytes into the tissues and further 
into the gingival sulcus, finally causing loss of collagen just apical to the junctional epithelium 
lining the base of the gingival sulcus (Page et al. 1997). If the biofilm is disrupted by tooth brushing 
or by professional root scaling, the process is reversed and healing occurs (Kornman 1996). Without 
removal of the subgingival plaque, the condition may progress into periodontitis (Page 1991; Page 
et al. 1997). 
 
Periodontal health indices are used in clinical practice to define a patient´s present gingival status as 
well as for following any changes in gingival status over time (Beck & Arbes Jr 2006). According 
to the international database (WHO, http://www.whocollab.od.mah.se/index.html) severe 
periodontitis is found in 5-15% of most populations. Results from a large Finnish national health 
survey reveal that periodontal diseases are a significant national dental health problem among 
dentate adults over 30 year of age. The prevalence of periodontitis was found to be 72% in men and 
in 57% in women (Kansanterveyslaitos 2004).  
 
3.5.1 Periodontal microbiology 
The mouth, being moist and having a high concentration and availability of different nutrients, is an 
ideal environment for the growth of micro-organisms. Also, as the temperature in the oral cavity is 
approximately 37
o
C it offers a good environment for bacterial growth (Meurman et al. 2009).  The 
presence of different surfaces favours attachment and colonisation of bacteria, which further grow 
to form microbial biofilms to cover the teeth and mouth mucosa. It has been shown that thick 
microbial plaques may form on teeth, where bacterial concentrations up to 10
9
 colony forming units 
per mg have been detected (Li & Caufield 1995). The microbial communities are usually fairly 
stable throughout life, but the density of micro-organisms varies depending on a subject’s health 
and disease status, oral hygiene practices, and diet (Li & Caufield 1995; Lee et al. 2006). By the 
beginning of the 21
st
 century over 700 microbial species had been identified in the mouth (Paster et 
al. 2001; Kazor et al. 2003). In addition, a recent study reported signs of thousands of unidentified 
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micro-organisms in oral samples analysed with a molecular pyrosequencing technique (Keijser et 
al. 2008). 
 
For oral diseases it is has been suggested that a small group of predominately Gram-negative, 
anaerobic or microaerophilic bacteria within the biofilm are often associated with periodontal 
disease initiation and progression (Page & Kornman 1997). Among those subgingival bacteria 
which are currently associated with periodontal diseases are the Gram-negative, strictly anaerobic 
bacteria species: Porphyromonas gingivalis (P.g.), Prevotella intermedia (P.i.), Tannerella 
forsythia (T.f.) (formely Bacteroides forsythus), Treponema denticola (T.d.), Fusobacterium 
nucleatum (F.n.) and the facultative/microaerobic bacteria Aggregatibacter (formerly 
Actinobacillus) actinomycetemcomitans (A.a.) and Campylobacter rectus  (American Academy of 
Periodontology 1996, 2005). The presence of different clonal types of these bacteria has been 
recognized. However, it is not known whether all clonal types are pathogenic (American Academy 
of Periodontology 2005). It is assumed that tissue destruction is caused when the population of the 
subgingival bacteria is high enough to overwhelm the host defense systems that prevent bacteria 
from migrating further subgingivally (Page et al. 1997). 
 
3.6 Saliva 
Saliva, a complex and versatile body fluid, is essential for oral health and functions (Lima et al. 
2010; Thelin et al. 2008). Saliva is critical for oral function as it is responsible for lubricating and 
protecting all surfaces in the oral cavity. The main function of saliva is to hydrate and cleanse the 
mouth as well as protect the teeth through its buffering and remineralizing properties, and to 
provide anti-microbial activity (Thelin et al. 2008). Saliva also takes part in many other important 
functions such as mastication, speech, deglutition and gustatory sensitivity (Sreebny & Valdini 
1988; Sreebny 2000; Mandel 1989; Lima et al. 2010). 
 
Saliva, as being a seromucous coating, is the principal defensive factor in the oral cavity. It 
lubiracates, protects oral tissues, act as a barrier against irritants by buffering and clearing, has 
antibacterial activity, and play a significant role in taste and digestion (Humphrey & Williamson 
2001). Low salivary flow has detrimental effects on teeth and mouth mucosa. Reduced salivary 
flow enhances oral microbial colonization, in particular by yeast. These, in turn, are an infectious 
burden on the patient and may worsen overall systemic health (Guggenheimer & Moore 2003). 
Reduced salivary secretion is also a risk factor for increased caries (Dodds et al. 2005) and for a 
reduced saliva pH and higher numbers of acidogenic micro-organisms (Almståhl & Wikström 
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2003). Salivary secretion follows a diurnal rhythm and it depends on the general state of hydration 
but is mostly affected by systemic diseases and drugs (Scully & Bagan 2004). A problem with 
salivary studies is that salivary flow rate and concentration values have huge variations both within 
an individual and between subjects (Mandell 1980).  
 
3.6.1 Composition 
Saliva is produced by the salivary glands. The major salivary glands are the parotid glands, 
submandibular glands and sublingual glands. Minor glands are situated on the tongue, palate, lip, 
and buccal and labial mucosa (Ferguson 1999). In the salivary glands there are acinar cells, various 
duct system cells, and myoepithelial cells. The branched ductal system and the secretory end pieces 
(acini) are responsible for the saliva secretion from the salivary gland tissues. The duct system of 
the submandibular and parotid glands is well-developed and well–branched. It contains intercalated, 
striated and excretory ducts.  Simple branched tubular glands are classed as minor salivary glands 
(Tenovuo & Lagerlöf 1994). The site of formation of the saliva is the acini which secrete the 
primary saliva and determine the type of secretion (mucous or serous) saliva produced from the 
different glands (Humphrey & Williamson 2001). The plasma-like isotonic primary saliva is 
secreted by acinar cells. The secreted fluid first passes through intercalated ducts to the striated 
ducts where ions are actively extracted, rendering this primary saliva progressively more hypotonic 
to enable it to pass down through excretory ducts and towards the mouth (Despopoulos & 
Silbernagl 1991; Smith 1996). The serous secretions are produced mainly from the parotid gland 
and mucous production from the minor glands. Mixed secretions of serous and mucous secretions 
are produced by the sublingual and submandibular glands (Edgar 1992). Whole saliva is a 
combination of fluids from the major and minor salivary glands along with gingival crevicular fluid 
(GCF), which contains oral bacteria and food debris (Edgar 1992; Dawes 2008). The major salivary 
glands contribute most of the secretion in terms of volume. However, minor gland secretions 
modify the properties of the saliva and thereby cause variation in the type of protection given by the 
secreted saliva. Minor glands also contribute the blood-group substances of the saliva (Humphrey & 
Williamson 2001).  
 
Whole saliva is a dilute fluid that is almost 99% water (Humphrey & Williamson 2001).  Organic 
and inorganic solid components are dissolved in the aqueous component and they vary widely from 
one individual to another. Variations in solid components occur even in the same individual over 
the course of the day (Lima et al. 2010). The inorganic part of saliva is composed of weak and 
strong ions. Na, K and Cl are the most important ions for maintaining the ionic strength of saliva.  
  
24 
 
Ca, Mg, and phosphates have an important role in mineralisation events.  Epithelial cells lining the 
salivary ducts produce bicarbonate ions. When the salivary gland is stimulated, salivary flow rate 
increases and the production of bicarbonate increases. Bicarbonate acts as buffer and maintains the 
pH level of close to 7. Saliva is slightly acidic. The normal pH of saliva is 6-7. However, it can vary 
from 5.3 to 7.8 depending on the state of the flow (Humphrey & Williamson 2001). The organic 
part of saliva is composed mainly of amylase (α-amylase), antimicrobial salivary proteins, serum 
filtrates, nitrogenous products (urea and ammonia), and lipids such as cholesterols and fatty acids 
(Tenovuo & Lagerlöf 1994; Humphrey & Williamson 2001; Lima et al. 2010). 
 
Almost 400 different proteins have been identified in saliva (Tenovuo & Lagerlöf 1994; Hofman 
2001; Lima et al. 2010). In the saliva the most relevant proteins derived from the salivary glands are 
α-amylase, histatins, cystatins, lactoferrins, lysozymes, mucins and proline-rich proteins and 
statherin (Hofman 2001). Amylase is generally considered to be a reliable marker for serous cell 
function (Almståhl et al. 2001). The salivary proteins albumin and transferring are derived from 
plasma (Hofman 2001). Of the plasma proteins, albumin is the most abundant, accounting for more 
than 50% of all proteins in plasma. Although salivary albumin has been regarded as a serum ultra-
filtrate (Oppenheim 1970) it may also diffuse into the mucosal secretions (Schenkels et al. 1995). 
Salivary albumin has been suggested to be a useful tool for diagnosting periodontitis. Higher 
salivary albumin concentrations have been found in patients with periodontits than in healthy 
dentate and edentulous patients (Takahashi et al. 2004) and in patients with gingivitis or 
periodontitis compared with healthy subjects (Henskens et al. 1993). Also albumin is selectively 
absorbed by different materials in the oral cavity and therefore it can attach to specific bacteria, and 
thus alter the composition of dental plaque (Kohavi et al. 1997). Salivary albumin levels have also 
been used as a marker for the degree of mucositis (Oppenheim 1970), and it has been suggested that 
albumin analyses may be useful in assessing the integrity of mucosal function in the mouth 
(Meurman et al. 1997b). Increasing albumin levels were seen in medically compromised patients 
whose general condition getting worse (Meurman et al. 2002) and also high concentration levels of 
albumin were detected in HIV-infected patients (Mellanen et al. 2001). Salivary albumin has also 
been used as a marker for salivary gland inflammation (Fox et al. 1985; Schiodt et al. 1992). 
 
The immunological contents of saliva include secretory IgA (sIgA), IgG and IgM. IgA is produced 
by plasma cells in connective tissues and it is then translocated through the duct cells of the major 
and minor salivary glands to be added to the saliva (Humphrey & Williamson 2001). sIgA is a 
largest immunologic component of saliva (Bulkacz & Caranza 2006). The other immunoglobulins 
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in saliva are believed to enter the saliva mainly as components of GCF, and they are present in 
lower quantities than IgA (Humphrey & Williamson 2001). The IgG is mainly derived from serum, 
but a minor fraction may originate from local plasma cells when the gingivae are inflamed 
(Kaufman & Lamster 2000). It is not known whether locally produced and serum-derived IgM and 
IgG can also be transmitted paracellularly to saliva via oral mucosa.  
 
Different components of saliva interact with each other and have important functions. Although 
they generally occur in small amounts and vary with changes in salivary flow, they continually take 
part in important and essential functions (Humphrey & Williamson 2001). One of these functions is 
the modulation of pH and buffering capacity by bicarbonates, phosphates, proteins and urea. 
Macromolecule proteins and mucins play roles in cleansing, aggregating, and/or attachment of oral 
microorganisms and contribute to dental plaque metabolism. Ca, P, and proteins work together as 
antisolubility factors and they also modulate demineralization and remineralisation. 
Immunoglobulins, proteins and enzymes are responsible for the antibacterial propeties of saliva 
(Humphrey & Williamson 2001).  
 
3.6.2  Flow rate 
The main factor affecting the salivary composition is the salivary flow rate (Tenovuo & Lagerlöf 
1994). The flow rate is influenced by many factors including the degree of hydration, drug use, 
body position, previous stimulation, and circadian rhythm as well as the size of salivary glands 
(Dawes 2004). Salivary glands are innervated by parasymphathetic and symphathetic nerve fibers. 
These two types of nerve fibres produce different ratios of activation by different stimuli and the 
type of stimulation results in changes in consistency of the secreted saliva ie. more watery saliva or 
less watery saliva (Tenovuo & Lagerlöf 1994). 
 
The normal average daily flow of whole saliva in adults varies from 1 to 1.5 litres (Edgar 1990; 
Humphrey & Williamson 2001). Lower estimates (0.6 L/24 h) have also been made for the normal 
daily production of saliva (Watanabe & Dawes 1988). When measuring and reporting salivary flow 
rates, the results are usually given as unstimulated and stimulated flow rates. Unstimulated whole 
saliva is the mixture of secretions which enter the mouth in the absence of exogenous stimuli such 
as chewing, whereas stimulated flow is secreted in response to masticatory stimulation, or to 
stimulation of vagal afferent fibers at the gastric end of the esophagus (Ganong 1989).  
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Dawes (1987) has provided a standardized protocol to measure the whole saliva flow rate. The 
generally accepted limit for a very low unstimulated whole saliva rate is ≤0.1 ml/minute (Sreebny & 
Valdini 1988; Edgar 1990). Values between 0.1 to 0.2 ml/min are considered to constitute low 
unstimulated flow rates, and values above those represent a normal unstimulated flow rate (Sreebny 
& Valdini 1988; Tenovuo & Lagerlöf 1994). Correspondingly, stimulated saliva flow rates below 
0.1 ml/min are considered to be very low (Sreebny & Valdini 1988), and those below 0.7 ml/min 
are considered to be low (Sreebny & Valdini 1988; Edgar 1990; Närhi 1994). A wide variation 
among individuals has been found (Ghezzi et al. 2000) and ideally the saliva flow rate should be 
recorded as a base reference value after the age of 15 (Edgar 1990). However, there is no uniformly 
accepted reference value for saliva flow rates, and therefore clinical practice and recommendations 
vary (Ship et al. 1991b).  
 
Reduced salivary flow enhances oral microbial colonization, in particular colonization of yeasts 
(Pajukoski et al. 2001). These factors, in turn, can cause an additional infection load in the patient 
and may worsen the systemic condition (Guggenheimer & Moore 2003). When sleeping, 
unstimulated saliva is the moisturizing and lubricating component of the oral defense system, and a 
decrease in its secretion may be indicated by dry mouth and burning mouth symptoms (Pajukoski et 
al. 2001).  
 
The sensation of DM and its relation to minor gland saliva secretion has recently been studied 
(Eliasson et al. 2009). Eliasson et al. (2003) reported earlier that flow rate of labial gland saliva can 
increase, and the complaints of DM increase, in postmenopausal women treated with a low potency 
estrogen treatment. According to the study by Eliasson et al. (2009) the impaired saliva film 
retained on the oral surfaces seems to have important role in the sensation of oral discomfort, and 
the secretion of minor salivary glands may contribute considerable to this film, especially in the 
mucosa. Therefore these results indicate the importance of further studies on the role of minor 
salivary glands in DM (Eliasson et al. 2003; Eliasson et al. 2009). 
 
3.6.3 The diagnostic use of saliva in normal dental practise 
Saliva analysis has become important, and is useful for evaluating physiological and pathological 
conditions in humans in the fields of medicine and dentistry. The use of saliva has many 
advantages. It is easily obtainable, sample collection is non-invasive and easy, and storage is low 
cost (Lima et al. 2010). Due to the origin of saliva and its composition and functions, as well as its 
interactions with other organ systems, it is a useful tool for diagnosing various diseases (Lima et al. 
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2010). Saliva is also valuable for monitoring some drugs (Lillsund 2008), hormones and antibodies 
(Smith et al. 1991; Tabak 2001).   
 
It is evident that, in dental practice, salivary measurements, at least salivary secretion rates and 
buffering capacity, should be used to supplement the anamnestic information and clinical findings 
with regard to prevention of dental caries (Tenovuo & Lagerlöf 1994). For normal dental practice 
the salivary bacterial counts are used for caries risk assessment. Dip slide tests are widely used and 
they are based on the identification and quantification of Lactobacillus species and mutans 
streptococci in the saliva. These bacteria are associated with caries development (Tenovuo & 
Lagerlöf 1994; Lima et al. 2010). Identifying those bacteria through saliva tests could strengthen 
preventive measures against caries development (Lenander–Lumikari & Loimaranta 2000). 
However, the tests that are currently available are useful for estimating caries activity due to bad 
dietary habits, and establishing the presence of infection and salivary yeasts (Larmas 1992).  
 
In the majority of adult patient yeasts, mainly Candida albicans, are found to live commensaly in 
the oral cavity, mucosal surfaces being the primary reservoir (Odds 1988). Yeast colonization has 
also been demonstrated in prostheses, dental plaque and in periodontal pockets (Pizzo el al. 2002). 
However, a major factor associated with overgrowth of the yeast is a diminished host resistance as a 
result of some diseases (Rees 2006).  A chair-side method (Oricult ®) has been developed for 
detecting yeast easily from the saliva in the clinical practise. 
 
The use of saliva as a diagnostic and monitoring method for periodontal diseases has also been 
increasingly studied (Kaufman & Lamster 2000). Results from the population study by Könönen et 
al. (2007) showed that carriage of periodontal pathogens in saliva was common, since at least one of 
the studied pathogens was found in the saliva of 88% of the subjects. Monitoring the carriage 
pattern of periodontal pathogens from saliva samples at the general population level could therefore 
help in designing preventive strategies to control the acquisition of less beneficial members of the 
human oral microbiota (Könönen et al. 2007). 
 
A problem with the reliability of using saliva samples to determine types and levels of compounds 
in circulation is that concentration of the biochemical compounds in plasma are defined with well 
documented reference values whereas oral fluid composition exhibits a wide variation both 
quantitatively and qualitatively. However, saliva is currently used in the measurement of some 
steroid hormones (Chiappin et al. 2007), although not all the hormones are found in saliva. To date, 
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there is no clear explanation for why some hormones can be found in saliva and some cannot 
(Gröschl 2009). Lipid-soluble steroids or amines are transfered more rapidly to the saliva than 
hydrophilic peptides, and hydrophilic conjugates are more likely transferred by ultrafiltration 
(Vining et al. 1983; Riad Fahmy et al. 1983; Gröschl 2009). Salivary concentrations of conjugated, 
lipid-insoluble hormones like cortisone, dehydroepiandrosterone sulphate (DHEAS), thyroxine and 
pituitary hormones are much lower than (1-20%) than the unbound plasma concentration, and 
therefore salivary analyses are of less value for these hormones (Vining et al. 1983; Vining & 
McGinley 1987; Read 1989) .  
 
3.7 Menopause 
 
3.7.1 Definition 
Natural menopause is defined as a spontaneous cessation of natural menstruation for 12 consecutive 
months at 45-55 years of age (mean 50-52) (McKinlay et al. 1992; Oldenhave et al. 1993; Gold et 
al. 2001).  Formally, menopause is the moment of the final menstruation, directly preceded by the 
permanent cessation of ovarian follicular function (Morabia & Costanza 1998; Nelson 2008). The 
average age of a woman at menopause is 51 years (McKinlay et al. 1992; McKinlay 1996; Rutanen 
& Ylikorkala 2004).  
 
Menopause results from reduced secretion of the ovarian estrogen, which takes place when ovarian 
follicles are depleted through genetically controlled apoptosis of the ovarian cells. During the 
menopausal transition the level of inhibin B originating from the follicles decreases and the levels 
of pituitary follicle-stimulating hormone (FSH) and luteinizing hormone (LH) increase. As the level 
of FSH rises, small ovarian follicles temporarily undergo activation, and this leads to increases in 
circulating E2 levels at an early stage of the menopausal transition. However this occurs only at the 
period of transition and is not seen in all women. Nevertheless, hypoestrogenism is the ultimate 
outcome of menopause. With increasing age, the levels of FSH and LH continue to rise for several 
years, but in later menopause these levels decrease (Kase 2009). 
 
WHO has defined three age stages of midlife age for women (Research on the menopause. WHO 
1996): “1) Menopause is the year of the final physiologic menstrual period retrospectively 
designated as 1 year without flow (unrelated to pregnancy or therapy) in women aged ≥ 40 years. 2) 
Premenopause begins at ages 35 to 39 years; during this stage, decreased fertility and fecundity 
appear as the first manifestations of ovarian follicle depletion and dysfunction, despite the absence 
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of menstrual changes. 3) Perimenopause includes the period of years immediately before the 
menopause and the first year after the menopause.” A model developed at the Stages of 
Reproductive Aging Workshop (STRAW) describes seven stages of reproductive ageing (Figure 1)
(Soules et al. 2001). 
Figure 1. Stages and nomenclature of normal reproductive aging in women (figure modified from 
Soules et al. 2001). 
Diagnosis of menopause is complex as it can be made only retrospectively as menopause is defined 
as the onset of the last menstruation, followed by amenorrhea. Therefore the term “menopausal 
transition” has been used to refer to the first year of amenorrhea that marks the end of 
perimenopause and begins the postmenopause phase (Prior 1998; Martin & Mason 2008).  
The term postmenopause is defined as the prolonged period of hypergonadotropic hypogonadism 
after menopause. Postmenopause is further divided into two different stages: early postmenopause, 
when estrogen is swiftly declining, and late postmenopause, when prolonged hypoestrogenism 
exists (Speroff & Fritz 2005). Climacterium consists of the transition period from fertility to 
infertility of which menopause (the last menstruation) as well as perimenopause and postmenopause 
are parts.  
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3.7.2 Consequences of menopause 
 
3.7.2.1 Climacteric symptoms 
The endocrine changes during perimenopause manifest as annoying clinical symptoms (Kase 2009). 
The symptoms which may occur before and/or within the first months of menopause are defined as 
immediate symptoms. Most characteristic for menopause are vasomotor symptoms such as hot 
flushes and night sweats, which are present in 75-80% of all women in menopausal age groups 
(Oldenhave 1993; Stearns et al. 2002; Deecher & Dorries 2007). Quality of life is greatly reduced 
because of VMS (Luoto 2009). Vasomotor symptoms are causally related to decreasing E2 
concentrations, mainly in the serum and subsequently also in the hypothalamic temperature 
regulating centre (Rossmanith & Ruebberdt 2009). Immediate symptoms have become a leading 
reason for initiating HT in clinical practice (Lyytinen 2009).  
 
Other symptoms which are commonly linked to the climacteric stage are mood swings, urogenital 
dryness, tiredness, joint and muscle pains, dizziness, irritability and insomnia (Kenemans et al. 
2001; Stearns et al. 2002; Nappi & Lachowsky 2009). In a Finnish study, 46% of women aged 52-
56 years had moderate or severe climacteric symptoms and only 5% were asymptomatic (Jokinen et 
al. 2003).  
 
Also, oral symptoms such as sensation of DM and sensation of PM have been listed among 
symptoms that occur at menopause. In clinical practice, the majority of BMS patients seem to be at 
menopause or are postmenopausal women (Basker et al. 1978; Speciali & Stuginski-Barbosa 2008). 
 
3.7.2.2 Osteoporosis  
Data has established an association between low estrogen levels and bone loss (Waugh et al. 2009). 
Both bone–forming osteoblasts and bone-resorpting osteoclasts express estrogen receptors ERα and 
ERβ. This indicates that bone is a target for estrogen (Bord et al. 2001). It is known that estrogen 
reduces the activity of osteoclasts and increases their apoptosis, thus decreasing postmenopausal 
bone loss (Manolagas 2000). HT has shown a bone strengthening effect both in the spine and hip 
after 2 years of treatment (Wells et al. 2002). Estrogen use has been associated with a reduction of 
osteoporotic fractures of up to 40-59% (Farquhar et al. 2009). 
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According to the WHO criteria, osteoporosis is diagnosed when bone mineral density is at least 2.5 
standard deviations below the average value for young and healthy women (T-score < -2.5). In 
Finland, it is estimated that approximately 400 000 people have osteoporosis, and annually 30, 000-
40, 000 osteoporotic fractures are diagnosed (The Finnish Current Care guidelines, Finnish Medical 
Society Duodecim, www.kaypahoito.fi). 
 
3.7.2.3 Cardiovascular diseases 
Cardiovascular diseases (CVD) are rarely diagnosed in premenopausal women compared with age-
matched men (Isles et al. 1992).  According to results from Pepine et al. (2006) clinically significant 
CVD occurs in women approximately 10 years later than in men. However, menopause has been 
known to be associated with the incidence of CVD (Collins et al. 2007; Shaw et al. 2009). 
Menopause is known to induce hypoestrogenism and this has been suggested to be one of the 
explanatory factors for this association (Mendelsohn & Karas 2005). 
 
3.8 Hormone therapy 
 
3.8.1 General principles 
Estrogen therapy to treat menopausal symptoms has been used worldwide for more than 80 years 
(Barrett-Connor 2003; Warren 2004; Stefanick 2005). However, already before 20
th
 century 
treatments for the “climacterica” were described. Pills containing powder from derivates of dried 
cow ovaries were used until derivatives from human pregnancy urine were developed (Stefanick 
2005). In 1942, products from the urine of pregnant mares were combined and developed for HT by 
Wyeth-Ayerst (Ltd. of Canada). This, the world's first conjugated estrogen medicine, named 
Premarin, was then approved by US Food and Drug Administration (FDA) for treating menopause 
(Stefanick 2005;  http://en.wikipedia.org/wiki/Wyeth-Ayerst).  
 
Natural human estrogens are E2, estrone (E1) and estriol (E3), and their conjugates, i.e. the sulfuric 
acid esters (sulfates) and glucuronic acid esters (glucuronides) (Kuhl 2005).  E2 is considered the 
most potent of these. Estrogen-only therapy (ET) can be prescribed to hysterectomized women 
(Kuhl 2005) and it is used either orally or transdermally. In Europe the predominant estrogen for 
HT has been E2 whereas in the US conjugated equine estrogen (CEE; from mares urine) is most 
commonly used (Campagnoli et al. 2005; Kuhl 2005). 
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The use of ET in women with an intact uterus is associated with an increased risk of endometrial 
cancer (Smith et al. 1975; Ziel & Finkle 1975; Furness et al. 2009). Therefore, progestagen as a 
complement to oral or transdermal estrogen treatment (estrogen-progestagen therapy; EPT) is 
needed in non-hysterectomized women in order to protect the endometrium against hyperplasia and 
malignant transformation (Manson & Martin 2001). 
 
Progestagens are divided into natural progesterone and synthetic progestagens (Schindler et al. 
2008). In Europe a large variety of different progestagen products are available. In Scandinavia and 
the UK norethisterone acetate (NETA) and levonorgestrel (LNG) are more preferable used. The 
most common progestagen used in US is medroxyprogesterone acetate (MPA), while in Europe 
MPA is used to a lesser extent (Campagnoli et al. 2005). MPA is known to have some 
antiestrogenic, androgenic and glucocorticoid properties which may counteract the beneficial 
effects of estrogen (Kuhl 2005). 
 
Synthetic steroid tibolone, various phytoestrogens, testosterone and selective estrogen-receptor 
modulators (SERM) are used under some conditions as alternatives to traditional HT (Kuhl 2005; 
Campagnoli et al. 2005). Of these, only tibolone is effective and useful in treating vasomotor 
symptoms. 
 
Human fetal steroid estetrol (E4) was previously considered to be a weak estrogen, but recent 
research has demonstrated that it is an effective estrogen agonist with estrogen antagonistic effects 
on the breast in the presence of E2 (Coelingh Bennink et al. 2008). Based on its pharmacokinetic 
properties, especially its slow elimination, long half-life and oral bioavailability, it seems 
potentially suitable as a drug for human use as an adjuvant in HT (Visser & Coelingh Bennink 
2009). 
 
3.8.2 Use of hormone therapy 
Women are treated with HT not only to avoid climacteric symptoms but also to protect them from 
CVD and osteoporosis (Grodstein & Stampfer 1995; Seeman et al. 1995). However, as evidenced 
by numerous studies, endogenous hyperestrogenism is associated with an elevated risk for breast 
cancer, therefore it is expected and also it has been confirmed that also the use of exogenous female 
sex hormone may increase the risk for breast cancer (Collins et al. 2005; Lee et al. 2005; Lyytinen 
2009). Recently the use of HT has received much publicity when the results from large population 
studies, The Heart and Estrogen/Progestin Replacement Study (HERS) of 2763 postmenopausal 
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USA women with CVD and average age of 67 years in 1998, the USA study Women’s Health 
Initiative (WHI) of 16,608 postmenopausal women (aged 50 to 79 years) in 2002, and a study of 
1,084,110 UK women aged 50-64 years, the Million Women Study (MWS) in 2003, were 
published. These studies suggested that the benefits of using HT for the prevention of diseases other 
than menopause-associated symptoms may not be warranted (Hulley et al. 1998; Rossouw et al. 
2002; Beral 2003). Before the publication of the results from HERS, it was recommended that 
postmenopausal women consider taking HT based on the diverse beneficial effects such as the 
reduction in risk of osteoporosis and heart disease (Ballard 2002). After the results from the trials 
(HERS, WHI, MWS), the European Medicines Agency (EMEA) recommended that HT should only 
be used for severe menopausal symptoms over short periods (EMEA 2003).  
 
As a result of these studies and recommendations, the use of HT has declined markedly since 2002 
in many countries, including Finland (Lawton et al. 2003; Hersh et al. 2004; Tiihonen et al. 2007).  
Recent experimental and clinical studies have indicated that the effects of HT depend on the 
estrogen and progesterone/progestin formulation, dosage, mode of administration, patient's age, 
associated diseases, and duration of treatment (Harman 2006; Caufrietz 2007).  
 
However, there is no doubt that many women clearly benefit from the use of HT, which may also 
have implications in the oral cavity (Friedlander 2002). HT at the lowest effective dose is now 
recommended as an established treatment for healthy, recently postmenopausal women suffering 
with disturbing moderate to severe hot flushes (Rutanen & Ylikorkala 2004; International 
Menopause Society Consensus Statement 2009). According to further analysis of WHI data it was 
revealed that women who started HT within 10 years from the onset of menopause had a reduced 
risk of coronary heart disease, compared with those who started HT later than 10 years of onset of 
menopause (Rossouw et al. 2007). 
 
In Finland in 2008, various forms of HT were used by a total of 352, 600 postmenopausal women 
(Paakkari et al. 2008). According to The Finnish Medical Society and the Academy of Finland 
2004, the use of HT can be continued as long as it improves the quality of life, and therefore there is 
no upper limit defined for the duration or the age of women using HT. 
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3.8.3 Estrogen receptors (ERs) 
Estrogens are the main female sex steroids. They are known to control and regulate many cellular 
processes including growth, differentiation and function of reproductive as well as non-productive 
tissues and systems. The most important estrogenic hormone, E2, is synthesized in the ovary and in 
the other tissues by aromatization of testosterone (Hollihn 1997; Gruber et al. 2002). E2 is involved 
in the control of sexual behaviour and reproduction functions, differentiation of several tissues and 
organs, modulation of inflammation, and brain and cardiovascular function (Gruber et al. 2002; 
Deroo & Korach 2006). Estrogens are also suggested to be involved in the regulation of tissues such 
as bone, tooth and periodontium (Hollihn 1997; Mariotti 1994). In the non-pregnant female, E1 and 
E2 are the main forms of estrogen. E3 is is the main estrogen during pregnancy. Unbound estrogens 
are diffused from the bloodstream into their target tissues. The biological effects of estrogens are 
based on genomic mechanisms that are mediated by interactions and with activation by the nuclear 
ERs in these target tissue cells (Jensen et al. 1972; Ray et al. 2002; Marino et al. 2006). Two 
different subtypes of ERs have been identified so far:  ERα (Greene et al. 1986) and ERβ (Kuiper et 
al. 1996). ERα has been found in commonly known estrogen-target tissues (mammary glands and 
the endometrium), whereas ERβ has also been detected in more unexpected target tissues such as 
colonic (Campbell-Thompson et al. 2001) and prostatic epithelia (Kuiper et al. 1996). However, 
endocrinologists now have a target to develop specific agonists, which can selectively 
activate/inactivate either ERα or ERβ as it seems that in those tissues where both reseptors are 
expressed, they seem to work to counteract each other (Morani et al. 2008). Also, strong evidence 
has been recently presented demonstrating that ERβ has a role in estrogen signalling, along with its  
protective role in the epithelial-mesenchymal transition and in atherosclerosis as well as in 
regulation of cell proliferation in the colon (Zhao et al. 2010). 
 
The molecular structure of non-steroidal estrogens allows them also bind to the ERs. However, they 
do not fit exactly in the ligand-binding domain of the receptor protein, and this incomplete binding 
prevents the correct interaction necessary for induction of the normal biological function induced by 
E2. These structure-dependent characteristics and the existence of these two different ERs, ERα and 
ERβ, are the basis of the development of SERMs. The effects of phytoestrogens are also due to their 
binding to ERs, but their estogen activity differs largely from that of E2. It has been discovered that 
steroid and non-steroid molecules with less similarity to the structure of E2 have lower binding 
affinity for the ERs, and this dissimilarity correlates with their biological effect (Kuhl 2005). It is 
known that ER-mediated transcriptional activity is modulated by the actions of other nuclear 
receptors (Min et al. 2002).  
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Endorcine-disrupting chemicals are xenobiotics that can affect the healthy functioning of a variety 
of tissues by acting as potent estrogens by non-genomic signalling pathways, or by interfering with 
binding actions of physiological estrogens (Watson et al. 2010). The mechanism by which estrogen 
action is modulated by the environmental xenobiotics and their effects on human reproductive 
tissues are under investigation worldwide by various research teams (Crews & McLachalan 2006; 
Brucker-Davis et al.  2010). 
 
3.8.4 Sex steroid hormones and mouth   
Oral tissues are well vascularized, which means that the steroid hormone supply is good. Salivary 
glands and oral soft tissues contain sex steroid hormone receptors, which are typical of steroid 
responsive tissues. Earlier binding studies have shown that oral tissues are able to bind estrogen 
(Vittek et al. 1982; Dimery et al. 1987; Forabosco et al. 1992). Later immunohistochemical studies 
have shown the location of these receptors in oral mucosa, gingiva and salivary glands (Laine et al. 
1993, Ozono et al. 1992, Välimaa et al. 2004). Välimaa et al. (2004) demonstrated expression of 
ERβ subtype within oral epithelium and suggested a direct physiological role of ERβ to the oral 
mucosal, gingival and salivary gland function. In addition to blood circulation human oral mucosa 
and gingiva are exposed to steroid hormones by saliva. However, estrogen effects are mediated by 
both types of ERs in oral region. In contrast to salivary glands and oral soft tissues 
temporomandibular joint (TMJ) expresses ERα (Puri et al. 2009). In a recent study by Ribeiro-
Dasilva et al. (2009) suggested that a polymorphism in the ER may increase the risk of women 
developing TMJ. 
 
The steroid hormones detected in the saliva are thought to reflect the free, not protein bound, 
hormone concentration in blood (Hofman 2001). Hormones transfer from the blood to the saliva 
through the capillary endothelia and through the glandular epithelia (Gröschl 2009). The salivary 
level is a valuable clinical tool for those lipid-soluble hormones like cortisol (to show 
hypersecretion of endogenous cortisol), E2 (prediction for premature birth; a test-method approved 
by the FDA) and progesterone (Vining & McGinley 1986; Tivis et al. 2005).  
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3.9 Oral health, menopause and hormone therapy 
 
3.9.1 Oral symptoms in menopause 
In 1946 Ziskin and Moulton described a typical patient with oral symptoms as being a menopausal 
woman (Ziskin & Moulton 1946). In further studies, Massler (1951) found that patients with 
subjective oral symptoms were all at the same stage of menopausal transition. In his studies, 93% of 
the women complained of sensation of PM, 72% of abnormal taste sensation, and 90% of 
cancerphobia (Massler 1951). Wardrop et al. (1989) studied the relationship between oral 
discomfort and menopause in 149 women. They observed that the prevalence of oral discomfort 
was significantly higher in perimenopausal and postmenopausal women (43%) than in 
premenopausal women (6%). Their results also showed an association between oral discomfort and 
psychological symptoms in menopausal women. An Israeli group reported a high prevalence of oral 
discomfort in women attending a menopause clinic with a highly significant odds ratio (OR up to 
8.03) between systemic and oral complaints of menopause. They also observed a significantly 
altered salivary composition in the symptomatic women, pointing to sympathetic activation due to 
psychological stress (Ben-Aryeh et al. 1996).  
 
3.9.2 Oral symptoms and hormone therapy 
Approximately two-thirds of the menopausal women with oral discomfort but without oral clinical 
observed abnormalities, found that oral symptom were relieved with the use HT (Wardrop et al. 
1989). In Italy, the efficacy of HT was investigated in 27 postmenopausal patients with oral 
discomfort and in 47 postmenopausal women with no oral discomfort. The patients were treated 
with CEE and MPA. In that study HT did relieve oral symptoms in 15 of 27 patients who had 
reported symptoms (Forabosco et al. 1992). However, in this study HT had no effect on oral 
cytology in the 40 symptom-free postmenopausal women when compared with a control group of 
47 postmenopausal women who had no oral symptoms and were not treated.  The researchers 
further found nuclear ERs in 8 of 10 randomly selected patients with symptoms who responded to 
HT, but this result was not found in two patients who did not benefit from the therapy. The authors 
suggested that oral discomfort may be related to steroid hormone withdrawal only in some 
postmenopausal women and that HT may improve the clinical and cytologic features only in some 
patients (Forabosco et al. 1992). The same group also reported earlier that HT improved subjective 
and objective symptoms in 12 out of 22 patients treated with estriol and in 7 out of 10 patients 
treated with CEE plus NETA, suggesting that estrogen deficiency can be considered as a possible 
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cause of oral discomfort in some postmenopausal patients and that HT may indeed improve 
subjective symptoms of these patients (Volpe et al. 1991).  
 
Yalcin et al. (2006) observed in a 2-year clinical follow-up study on 348 Turkish women from 44-
65 years of age of whom 23% were using HT, that self-assesed sensation of DM was significantly 
less frequent among the hormone users than non-users (48.8% vs. 68.3%, p<0.05). Hakeberg et al. 
(1997) reported in their study on middle-aged and elderly women that female sex hormones were 
one of the predictors for occurrence of PM. They interpreted this result to indicate problems due the 
climacteric period. 
 
A questionnaire study by Jansson et al. (2003) observed more frequent xerostomia among 
postmenopausal women who did not use HT than in women using HT or in premenopausal women 
of the same age. The authors suggested that some of these oral symptoms might be related to 
estrogen deficiency, but that oral symptoms do not develop until some years after menopause. It 
may also be that women with the most severe symptoms decided to use HT and use of HT 
decreased their symptoms to the same level as in non-users (Jansson et al. 2003). 
 
However, attempts to relieve menopausal symptoms such as hot flushes with medication may even 
worsen symptoms of the mouth. Grady et al. (2007) reported in a randomized controlled 6-week 
trial that, compared with placebo, antidepressant sertraline was ineffective in reducing the 
frequency of hot flushes but caused a number of unpleasant side effects, including dry mouth.  
 
3.9.3 Periodontal health and menopause 
Female gender–related hormonal conditions, such as pregnancy- and puberty-associated gingivitis 
are known as temporary periodontal diseases (American Academy of Periodontology 2005; 
Armitage 1995). A number of studies have linked menopause with periodontal conditions.  
Osteoporosis and alveolar bone loss and periodontitis in addition to menopause are often assessed 
together which make that literature difficult to analyse. There is a lack of studies linking only 
menopause or an estrogen-deficient state to susceptibility to periodontal disease (Mascarenhas et al. 
2003; Kinane et al. 2006). However, systemic bone loss may be a risk indicator for periodontal 
destruction (Tezal et al. 2000), and increased rates of bone mineral density loss after menopause are 
associated with greater risk of tooth loss (Krall et al. 1994). Hence, prevention and treatment of 
osteoporosis after menopause may also have broader oral health consequences (Krall et al. 1994; 
Eviö et al. 2006). 
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3.9.4 Periodontal health and hormone therapy 
Targets for potent sex hormones such as androgens, estrogen and progesterone have been localised 
in periodontal tissues (Gornstein et al. 1999). As stated in a review by Mascarenhas et al. (2003) a 
number of studies have shown that changes in periodontal conditions might be associated with 
variations in sex hormone levels. Recently Haas et al. (2009) reported that the prevalence of 
periodontitis was significantly greater in postmenopausal women not using HT than premenopausal 
women. Postmenopausal women using HT and premenopausal women had similar periodontal 
status. Prior to that study Norderyd et al. (1993) showed that postmenopausal women (aged 50 to 64 
years) taking ET exhibited lower proportion of gingival bleeding units than an age-matched control 
group. However, Lopez-Marcos et al. (2005) found no significant effect on periodontal health 
parameters in a study group of 210 women receiving or not receiving HT. In contrast to these 
results, a study in 330 postmenopausal Japanese women showed that estrogen may promote tooth 
retention by strengthening the periodontal attachment surrounding the teeth, but not by increasing 
oral bone height or decreasing oral bone porosity (Taguchi et al. 2004).  In their results the duration 
of estrogen use was significantly associated with the number of remaining teeth (Taguchi et al. 
2004). The same group investigated also the affect of ER and vitamin D receptor gene 
polymorphisms and observed that certain gene polymorphisms indeed were associated with tooth 
loss (Taguchi et al. 2003).  
 
Meisel et al. (2008) in Germany found in a population-based epidemiological study of 4290 
participants that postmenopausal women who were using estrogen had higher number of teeth than 
men of the same age group. In addition women without hormone treatment had less teeth than other 
women in this study. This finding is in agreement with results from the Women´s Health Study 
from the United States were among the 42,171 postmenopausal women the overall risk of tooth loss 
was 24% lower in current HT users than in non-users (Grodstein et al. 1998).   
 
3.9.5 Saliva and menopause 
The composition of female saliva varies during different hormonal stages, such as during menstrual 
period and pregnancy (Tenovuo et al. 1981; Laine et al. 1988). In menopausal women the 
composition of saliva and decreased saliva flow seem to be estrogen-dependent (Leimola-Virtanen 
et al. 1997a; Bardow et al. 2001). However, medications are the major reason for impaired salivary 
function. Steroid hormones can be assessed in saliva samples and their salivary concentrations 
correlate with those in the blood serum (Vining & McGinley 1986; Tivis et al. 2005). 
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Salivary flow rate and the composition of saliva have been investigated in 42 menopausal women 
with/without xerostomia (21 cases, 21 controls) in a study from Iran (Agha-Hosseini et al. 2007). 
The results showed that the mean Ca-concentration in paraffin stimulated saliva was significantly 
higher in subjects with xerostomia than in controls (Agha-Hosseini et al. 2007). Recently Agha-
Hosseini et al. (2009) reported a case-controlled study on 76 non-medicated menopausal women, 
with an age range of 41-77 years old. The authors analysed salivary E2 concentrations and observed 
significantly lower E2 concentrations and stimulated salivary output among the 38 symptom cases 
than in the 38 controls. However, there did not find any significant correlation between stimulated 
flow rate and the severity of the self-assessed xerostomia in the women (Agha-Hosseini et al. 2009). 
This result was consistent with earlier studies by other investigators (Närhi 1994; Ben-Aryeh et al. 
1996; Agha-Hosseini et al. 2007). In contrast to these observations, Streckfus et al. (1998) showed 
that premenopausal women had higher salivary flow rates than postmenopausal women.  They 
compared stimulated salivary flow rates between three groups of females who were healthy 
Caucasian individuals from Baltimore, USA. The groups were divided according to their 
menopausal status. The study groups were premenopausal women (n=51), with a mean age of 39 
years, perimenopausal women (n=26), with a mean age of 48 years, and postmenopausal women 
(n=76) with a mean age of 69 years. They found that premenopausal women had higher salivary 
flow rates than postmenopausal women whereas no differences were found in salivary flow rates 
between women using HT or women not using HT (Streckfus et al. 1998).  
 
3.9.6 Saliva and hormone therapy 
Several authors who have shown that women who start using HT report improvement in their 
quality of life including less oral discomfort have suggested that improved saliva secretion is one 
reason behind the positive finding (Laine & Leimola-Virtanen 1996; Leimola-Virtanen et al. 1997a; 
Friedlander  2002;  Eliasson et al. 2003).  In a Swedish study, Eliasson et al. (2003) investigated the 
flow rate from minor salivary glands and the secretion rate and buffer capacity of whole saliva in 18 
postmenopausal women (61-76 years) prior to and during one year of low potency estrogen, ie. 
estriol (E3) use. HT caused a significant increase in the labial saliva flow and complaints of DM 
decresed. However, in this study increased stimulated whole saliva flow and better  buffer capacity 
were seen in both groups, indicating that an eventual HT effect on saliva flow is not that 
straightforward at all (Eliasson et al. 2003). A study from Turkey investigated saliva in a group of 
menopausal women (n=14) (average age 50.7 years) with osteoporosis treated with HT, and an 
equal number of non-menopausal controls (average age 42.4 years). They observed that the salivary 
flow rates decreased during the menopausal period and increased after HT use, while salivary pH, 
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electrolytes and calcium concentrations were not affected (Yalcin et al. 2005). However, Sewon et 
al. (2000) showed a decrease in salivary Ca-consentrations in 15 healthy menopausal (47-67 years) 
women treated with HT. 
 
The effect of HT on salivary peroxidase and IgA, IgG, and IgM, and on total protein in whole saliva 
was observed in 19 postmenopausal and 8 perimenopausal women by Leimola-Virtanen et al. 
(1997a). The mean concentrations of salivary IgA and IgG showed a significant time-related 
decrease (3 and 5 months after estrogen treatment) in both groups. The salivary IgM concentration 
in perimenopausal women also showed a significant time-related decline. Total IgA output per 
minute increased in perimenopausal women whereas it decreased in postmenopausal women. These 
results indicate that the composition of saliva in post- and perimenopausal women seems to be 
estrogen-dependent as regards these defensive factors of the mouth (Leimola-Virtanen et al. 1997a). 
However, HT seemed to have no effect on the amount of the total salivary bacteria in either 
perimenopausal or postmenopausal women (Leimola-Virtanen et al. 1997a). 
 
HT may thus improve both the quantity of saliva and the quality of salivary gland function in peri- 
and postmenopausal women (Laine & Leimola-Virtanen 1996). However, Ship et al. (1991a) 
showed in their study in the USA on 43 healthy premenopausal and postmenopausal females that 
there were no alterations in the quantity of saliva, suggesting that among healthy women salivary 
gland function is not significantly influenced by menopause or HT.  
  
These partly conflicting results need to be confirmed in larger studies as data on the effect of 
menopause on saliva is based on small patient numbers and no randomized controlled trials exist on 
the effect of HT on salivary secretion and composition (Elliasson et al. 2003; Meurman et al. 2009). 
It is also worth noting that doses of hormones that have been used earlier vary in formulation in 
different studies, and that hormone doses to relieve climacteric symptoms were higher in the past 
than those presently recommended for such symptoms (Nelson 2008).  
  
41 
 
4. THE HYPOTHESIS AND AIMS OF THE STUDY 
 
This investigation was based on the working hypothesis that there are differences in oral health 
between women using HT and those not using HT.  
 
The aim of this study was to investigate oral health and oral symptoms in women living in Helsinki, 
Finland who were at menopause (50- to 58-years-old) in years 1997 to 2001. The primary purpose 
was to explore whether women in this cohort who were using HT differed from non-HT users in 
dental habits, self-assessed oral and general health, oral symptoms and the oral health parameters 
studied. A questionnaire study and a clinical study were done to achieve these aims. A two-year 
follow-up study was carried out to evaluate possible changes in dental habits and self-assessed oral 
symptoms during the follow-up time. 
 
The specific aims of the present study were: 
1. To determine using a standardized questionnaire the use of HT and the prevalence of self-
assessed climacteric and oral symptoms such as sensation of pain (excluding toothache) and dry 
mouth  (Study I). 
 
2. To examine dental health clinically in a two-year follow-up study using WHO methods, and 
to evaluate self-assessed oral symptoms and dental habits by using a structured questionnaire 
(Study II). 
 
3. To determine periodontal conditions in a two-year follow-up study the based on the clinical 
and radiological findings, including microbiological evaluations of the periodontopathogens,  A. a., 
P.g., T.f., P.i. and P.n. by polymerase chain reaction (PCR) (Study III).  
  
4. To analyse salivary flow rates, total proteins, albumin, and IgA, IgG and IgM concentrations 
in a two-year follow-up study the (Study IV). 
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5. SUBJECTS AND METHODS 
 
This study was planned in co-operation with the Institute of Dentistry, University of Helsinki, the 
Department of Gynecology, Helsinki University Central Hospital, and the Helsinki City Health 
Department. The study plan was approved by the ethics committee of the City of Helsinki (ethical 
permit #53 1.4.1997). All subjects attending signed an informed consent agreement according to the 
Declaration of Helsinki.  
 
5.1 Subjects 
Study I 
Subjects were recruited from the women who attended a community mammography screening 
programme organized by the Helsinki City Health Department. Every year the health department 
invites and offers a free of charge mammography screening for all women citizens who are 50-, 52-, 
54-, 56- and 58- year of age. Yearly, approximately 20, 000 women are offered mammography. The 
response rate to the offer for screening has been around 77-85%. For the years 1997-1998, when 
this questionnaire study was conducted, the response rate for screening was 83% in 1997 and 86% 
in 1998 (communication, Dr. Jaakko Koskela). Altogether at the time of our study 24, 476 women 
participated in the communal mammography screening. 
  
When arriving at the mammography screening every fifth woman received our study questionnaire 
on oral symptoms. The women filled in the questionnaires at the mammography clinic and returned 
the forms to the nurse. Altogether 3182 women returned a filled-in form. Only 9 forms were filled 
in inappropriately and were excluded from the data analysis of the study.  Therefore altogether 3173 
completed questionnaires were used for further analyses. The questionnaire response rate was 65%.  
 
Studies II, III and IV 
Of these 3173 women, 40 who had reported in the questionnaire that they were using HT and other 
40 not using HT were randomized from each of the five age cohorts (50-, 52-, 54-, 56- and 58- 
years). These randomly selected women were invited for further clinical and radiographic 
examinations at the Institute of Dentistry, University of Helsinki. Altogether 400 women were 
invited by a mailed invitation letter. One reminder letter was send to those who did not respond to 
the first invitation. 249 women attended our baseline clinical study (response rate=62%). 
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Two years later those women who participated in our baseline study were re-invited to the follow-
up clinical examination. The study protocol followed the same model as at baseline. One reminder 
letter was send to those who did not response to our first invitation. Altogether 193 women 
participated in the follow-up study (response rate=78%). 
 
5.2 Study protocols 
 
Study I 
The structured questionnaire consisted of 36 questions on oral and general health.  
 
Studies II, III and IV 
Randomly selected women (from the selected age cohorts) were invited participate in the follow-up 
study. In the invitation letter women were asked to avoid eating, drinking and smoking for two 
hours before the appointment time. In the invitation letter it was pointed out that the free-of-charge 
examination would be non-invasive, and also that no dental treatment would be available or offered.  
 
When the women arrived at the dental clinic they were first given a questionnaire which consisted 
of the same questions asked in the primary questionnaire study. However, some additional 
questions on menopause status, and duration and type of used HT were included in this second 
questionnaire. This structured questionnaire consisted altogether of 51 questions on oral and general 
health (Appendix). After filling out the questionnaire, a panoramic tomography (PTG) of the jaws 
was taken. PTG was therefore available in the clinical examination to support clinical decision 
making.  
 
All clinical examinations and collection of the samples, and preparing the samples for the further 
biochemical analyses, as well as coding all the questionnaires for statistical analyses, were carried 
out by the same dentist (author L.T).  
 
The examination for each woman was carried out in the same order for everyone. At first, 
unstimulated and stimulated saliva flow rates were measured and recorded. Stimulated saliva was 
collected for further biochemical analyses. Dip slide tests were used to measure yeast counts and 
buffer capacity. Dental and periodontal status was recorded. Also, if according to the questionnaire 
the patient reported current sensation of PM, the cause of the pain was evaluated. After the 
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examination, the principal findings on dental status were explained to each patient, and if requested 
a written form as well as copy of the PTG was given to the patient to take to her own dentist. 
 
249 women participated in the baseline in our follow-up study. According to our inclusion and 
exclusion criteria, eleven women not using HT were excluded from the data because they were still 
menstruating regularly. Those excluded were statistically significantly (p<0.001) younger but 
otherwise they did not differ from the women included. Hence, after the baseline study, results for 
238 women were available for the baseline statistical analyses. 
 
HT had have been used for at least 6 months already in the beginning of the investigation in order 
for a woman to be regarded as an HT subject. Among these 238 women 138 were HT users and 100 
non-users. 
 
Of those 238 women who attended the baseline study 193 participated in the 2-year-follow-up 
study.  Of those participating in the follow-up, 32 women had changed their hormonal medication 
(started or stopped) during the intervening two years and were not included in the final statistics.  
Finally, statistical analyses of the results of this follow-up study were carried out for 161 women 
from which 106 women used HT during the two year interval and 55 women did not use. The study 
profile is illustrated in the flow-chart in Figure 2.  
 
Inclusion criteria as a HT user for the final analysis were: 
1) HT had been used for at least 6 months prior to the baseline study 
2) The HT was used during the intervening two years 
 
Exclusion criteria for final analysis were: 
1) Regular menstruation of non-HT users at baseline 
2) Changing from user to non-user of HT during the two year follow-up or vice versa. 
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Figure 2. Flow-chart of the study. 
4895 women (every fifth) was 
given a structured questionnaire 
Determined to be eligible 
for clinical study n=249 
Assigned to clinical 
baseline study n=238 
Not meeting 
inclusion 
criteria 
n=11 
Drop-outs 
n=45 
Two-year follow-up 
n=193 
Excluded due to 
change of HT 
group n=32 
 
Included in two year analyses 
n=161 
Hormone therapy users 
n=106 
Non-hormone therapy 
users n=55 
 
n=55 
400 out of 3173 menopausal 
age women were invited to 
join the follow-up study 
3173 women participated in a 
questionnaire study (Study I) 
Studies II, III and IV 
24,476 women participated in the community 
mammography screening 
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5.3 Measurements 
 
5.3.1 Questionnaire 
The structured questionnaire for Study I consisted of 36 questions and the questionnaire for the 
follow-up study (Studies II, III and IV) consisted of 51 questions. Questions concerned systemic 
medication, menstrual history (disturbances, menopause-age), climacteric symptoms and the use of 
HT and the type of HT, as well as oral symptoms and self-assessed general and oral health. Subjects 
were also asked about dental habits (daily tooth brushing and flossing) and frequency of dental 
check-ups. Use and duration of prescribed drugs as well as illnesses diagnosed by a physician were 
asked about with open ended questions. The other questions were mainly multiple-choice. 
 
5.3.2 Oral symptoms 
For the baseline study, oral symptoms were determined in the questionnaire with questions such as: 
“do you have sensation of pain in your mouth (excluding toothache)?”, and “do you have a 
sensation of dry mouth?” The multiple choice answers were: “1”; yes, “2”; yes previously, but not 
now, “3”; never. If PM or DM were reported at present, detailed questions on these conditions and 
treatment attempts followed in the questionnaire. Self-assessed oral health was also queried. 
Responses for multiple choice questions, and coding thereafter for statistical analyses were:  
“1” = good, ”2”=  fairly good, ”3” =  moderate, “4” =  fairly bad, and “5”= bad.  
 
For the 2-year follow-up study the same questionnaire was used.  If reporting PM in questionnaire, 
the cause was evaluated during the clinical examination. The corresponding coding of clinical 
evaluation was: “1” indicating  irritation by a removable prosthesis, “2” for malocclusion , “3” for 
periodontal problem, “4” for candida infection, “5” for lichenoid reaction, “6” no reason found 
(sensation of PM/BMS), “7” other oral mucosa lesion (in which case the subject was sent for further 
examination), and “8” for cortisone inhaler- induced irritation. For diagnosing the candida infection, 
results from the dip slide test were used. For codes 5, 6 and 7, if a biopsy was needed the subject 
was referred to the Department of Oral and Maxillofacial Diseases of Helsinki University Central 
Hospital.  
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5.3.3 Clinical dental recordings 
Clinical examinations were done according to the WHO criteria (WHO 1997). PTG was taken to 
support clinical findings. For dental status, the DMFT index was used. Decayed teeth (DT) and 
filled teeth (FT) indices were separately recorded. Teeth were classified as carious whenever one or 
more surfaces were assessed as needing restoration due to decay. Clinically detected retained roots 
were included in the DT score. Teeth with fractures or lost fillings without clinically observable 
caries were not categorized as carious. Because not all women remembered their history of dental 
treatment, all the missing teeth, whether they were extracted or congenitally missing, were 
calculated in the M-score of the index. Following the WHO criteria for the DMFT-index, the third 
molars were not taken into account. However, all erupted natural teeth, including third molars, were 
included with the DT and FT counts, and in the scores of the total number of teeth. 
 
5.3.4 Periodontal recordings and analyses 
5.3.4.1 CPITN 
To describe periodontal status, the WHO CPITN index was used. The periodontal examination 
involved evaluations of all surfaces of the teeth. The highest score per sextant was recorded and 
used in the analyses. According to the WHO Third edition of "Oral Health Surveys - Basic 
methods", Geneva 1987 CPITN is defined as follows: 
Recording  
Codes in descending order of severity are: 
4: pocket > 6 mm  
3: pocket 4 or 5 mm  
2: calculus felt during probing.  
1: bleeding observed, directly or by using a mouth mirror, after 
sensing with a probe. 
0: healthy           
 
The number of   6mm gingival pockets was recorded separately and “periodontitis” was diagnosed 
if at least one sextant had a CPI score of 3 or higher.  
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The presence of the periodontal bacterial species A.a., P.g., T.f., T.d., P.i. and P.n. was determined 
using PCR methods. The PCR method has been described in detail by Wahlfors et al. (1995) and 
Meurman et al. (1997a).  
 
Subgingival plaque samples were taken from the four deepest periodontal sites in every patient. If 
no ≥ 4 mm pockets existed or there were less than four ≥ 4 mm pockets in the subject the rest of the 
plaque samples were taken from the first premolars. Before sampling the supragingival sites, plaque 
was gently removed with a cotton swab and the site of collection was isolated with cotton rolls and 
dried. Thereafter, the subgingival plaque samples were taken with a sterile curette and placed into a 
micro-centrifuge tube containing 0.5 ml distilled water. The pooled samples were then centrifuged 
and 5 μl aliquots of supernatant were added to the PCR reaction mixtures.  
 
5.3.5 Salivary analyses 
Flow rates for unstimulate and stimulated saliva were measured as well as the buffer capacity of the 
saliva. The saliva collection was collected at the beginning of the clinical study in order to avoid the 
stimulus from the clinical examination. The subjects were asked to avoid eating, drinking and 
smoking two hours before the examination. Unstimulated saliva was collected for 3 minutes with 
the free flowing method.  For the stimulated saliva, a 1-gram piece of paraffin wax was given to the 
women to chew. The collection time for paraffin stimulated saliva was 3.5 minutes. Saliva collected 
during the first 30 seconds was discarded (for details see Meurman & Rantonen 1994). To 
determine the salivary buffer capacity, the Dentobuff Strip
®
-method (Orion Diagnostica Ltd., 
Espoo, Finland) was used. It was recorded according to the manufacturer’s guidelines (score 1: 
final-pH >6; score 2: final-pH 4.5-5.5; or score 3; final-pH less than 4.5). Yeast was analysed by 
use of the Dentocult CA
®
 dip slide method (Orion Diagnostica). This method mainly detects 
Candida albicans. The samples for the yeast analyses were taken with a sterile spatula from the 
tongue surface. After incubation for 5 days at 37C, the colony densities were recorded and 
classified into three groups of colony-forming units (CFU) as instructed by the manufacturer (score 
1: 0 to 20 CFU; score 2: 21-50 CFU; or score 3: more than 50 CFU).  
 
Salivary total protein, albumin, and IgA, IgG and IgM concentrations were analysed. Total protein 
was analysed with the colorimetric Lowry method, albumin was analysed according to Webster 
(1977), and the immunoglobulin concentrations according to Lehtonen et al. (1984). All analyses 
were made in duplicate with serum standards and appropriate controls. For details, see Mellanen et 
al. (2001).  
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5.4  Statistical analyses 
Descriptive statistical analyses were made using the Student t test or the analysis of variance 
(ANOVA), Mann-Whitney U-test, and the χ2 test when appropriate. Differences between the HT 
users and non-users were studied.  
 
For the baseline study (Study I) the multinomial logistic regression (LR) model was used to 
estimate the coefficients for proportional risk for PM and DM. The final model estimates were used 
to calculate odds ratios (OR) and 95% CIs. The estimations were done by using LIMDEP’s logit–
subroutines. 
 
For statistical analyses for the follow-up study (Studies II, III and IV), multiple logistic regression 
models were used to analyse the independent effects of the studied background variables on the 
probabilities of the dependent variables. Backwards elimination was used to control correlation 
between confounders. The model estimates were used to calculate odds ratios (OR) and 95% 
confidence intervals (CI). In all studies (I, II, III and IV), a probability value (p) of less than 0.05 
was considered to represent a significant difference. The SPSS for Windows versions 15, 17 and 
PASW Statistics 18 were used in analyses for Studies II, III and IV.   
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6. RESULTS 
Detailed results are given in the original publications and only the main results are presented here. 
6.1 Oral symptoms and hormone therapy (Studies I, II, III and IV) 
Study I 
Results were obtained from 3173 women who responded to the questionnaire study. HT was used 
by 46.8% (n=1486), and 53.2% (n=1687) were non HT users. The distribution of the type of HT in 
different age groups by 1415 HT users are given in Figure 3. 69 women did not specify the type of 
HT they were taking, but they were included in present study as HT users. 
As there were a few non-responses on the questions concerning PM or DM, the total numbers of 
observations used in analyses was 2946 for PM and 2973 for DM. PM was reported by 8.2% 
(n=259) and DM by 19.9% (n=631) of the total sample, respectively. There was no significant 
difference in the occurrence of PM or DM between the HT users and non users. The prevalence 
(%/n) of sensation of PM and DM in the selected variables for statistical analyses is more detailed 
seen in Study I. According to logistic regression analyses, climacteric complaints significantly 
correlated with the occurrence of PM (p=0.000) and DM (p=0.000) irrespective of the use of HT.  
Figure 3.  
Distribution of the type of HT (%) used by the studied age cohorts (50-58 years) (Study I).
ET =  Estrogen-only therapy 
EPT=  Estrogen progestagen therapy 
PT = Progestagen only therapy
0
10
20
30
40
50
60
ET (%)
EPT (%)
PT (%)
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Studies II, III and IV 
For the statistical analyses, the study population for the follow-up study consisted of 161 women. 
Out of them 66% (n=106) were HT users who had used hormone therapy on average for 3.9 years 
(SD 3.3). At the baseline, estrogen-only therapy (ET) was used by 48% (n=51), Estrogen-
progestagen therapy (EPT) by 50% (n=53) and progestin-only therapy (PT) by 2% (n=2). 
Corresponding results for the follow-up were 49% (n=49) for ET, 50% (n=53) for EPT, and 1% 
(n=1) for PT. There was no statistical difference in the distribution of the HT used during the two 
year follow-up time.   
 
In the questionnaire prior to the clinical examination PM was reported by 10% (n=11) of the HT 
users at the baseline and by 5.7% (n=6) two years later. For the non-HT users, corresponding 
figures were 12.7% (n=7) and 1.8% (n=1). 22.6% (n=24) of HT users complained of DM at the 
baseline and 21.6% (n=23) did so at the follow-up. For non-HT users, respective results for DM 
were 36.4% (n=20) and 28.8% (n=15). Descriptive data on the oral symptoms is given in Table 1.   
 
 
 
 
 
Table 1. 
Oral symptoms of the follow–up study subjects divided in groups according to the use of hormone 
therapy (HT) (Studies II, III and IV). (Pearson’s chi-square for categorical variables, Student’s t 
test and Mann-Whitney U test for continuous variables; independent samples t test for cross-
sectional study, and paired samples t test for prospective study). 
 
 Baseline 
  
Two-year  
follow-up 
    
 HT (106) Non-HT 
(55) 
p-value HT (106) Non-HT 
(55) 
Significance 
between 
groups 
Significance 
between 
baseline 
and follow-
up in HT 
group 
Significance 
between 
baseline 
and follow-
up in non- 
HT group 
Mean age 55.4 ± 2.7 55.9 ± 2.4 Ns. 57.4 ± 2.7 57.9 ± 2.4 Ns.   
Current climacteric 
symptoms 
16 (15%) 24 (44%) 0.000 14 (13%) 19 (35%) p < 0.001 Ns. Ns. 
Satisfactory self-
assessed dental health 
65 (61%) 28 (51%) Ns. 63 (59%) 31 (56%) Ns. Ns. Ns. 
Sensation of dry mouth 24 (23%) 20 (36%) Ns. 23 (22%) 15 (27%) Ns. Ns. Ns. 
Sensation of painful 
mouth 
11 (10%) 7 (13%) Ns. 6 (6%) 1 (2%) Ns. Ns. Ns. 
 
Ns. = Statistical difference not significant. 
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6.2 Dental and periodontal health and hormone therapy (Study II) 
According to a baseline questionnaire, HT users had visited a dentist less than year ago more often 
than non-users (p<0.05).  At the follow-up, this difference no longer existed. Tooth brushing at least 
twice daily was reported by 76% vs. 75% of HT users/non–users at the baseline and by 79% vs. 
69% at the follow up, respectively. There was no statistical difference between the groups in this 
respect (data not shown).  
 
The average DMFT index was 20.1 in the whole study group. There was no difference in DMFT 
index values between HT users and non-users.  In the HT group, the FT index score increased 
significantly during the follow-up (p<0.05). At baseline, self -assessed oral health was considered 
satisfactory by 61% of HT users and by 51% of non-users, and at the follow up by 59% and 
respectively 56%. These differences were not statistically significant. Descriptive data on dental and 
periodontal findings is given in Table 2.  
 
 
 
 
Table 2.  
Dental and periodontal findings in subjects using or not using hormone therapy (HT). Data is 
presented as means ± SD, or frequencies (n) with percentages (%). (Pearson’s chi-square for 
categorical variables, Student’s t test and Mann-Whitney U test for continuous variables; 
independent samples t test for cross-sectional studies, and paired samples t test for prospective 
testing). 
 
 HT (106)  Non-HT (55)  Significance 
 Baseline 2-year follow-
up 
Baseline 2-year follow-
up 
 
Number of teeth 25.0 ± 5.5 24.6 ± 5.6 23.5 ± 7.5 23.3 ± 7.5 Ns. 
DMFT 20.1 ± 4.3 20.9 ± 4.3 20.1 ± 4.7 20.2 ± 4.7 Ns. 
DT 0.4 ± 0.9 0.3 ± 0.7 0.5 ± 1.0 0.6 ± 1.3 Ns. 
FT 16.9 ± 5.3 17.6 ± 4.9 15.5 ± 6.3 15.6 ± 6.1 p < 0.05 
Subjects with periodontitis 83 (79%) 74 (71%) 43 (80%) 41 (76%) Ns. 
Number of  ≥6mm deep gingival 
pockets  
0.9 ± 1.7 1.1 ± 2.1 1.0 ± 1.7 1.2 ± 1.9 Ns. 
 
DMFT= Decayed missing filled teeth- index 
DT= Decayed teeth 
FT= Filled teeth 
Ns.= not significant 
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At baseline the percentage of women with periodontitis (defined as at least one sextant with a 
CPITN score of 3) was 79% in the HT group and 80% in the non-HT group. Two years later the 
respective figures were 71% and 76%. The mean numbers of ≥ 6 mm deep periodontal pockets 
were 0.9 ± 1.7 at baseline vs. 1.1 ± 2.1 two years later in the HT group, and 1.0 ± 1.7 vs. 1.2 ± 1.9, 
respectively, in the non-HT group. These differences were not statistically significant (Table 2). 
 
6.3 Periodontal microbiota and hormone therapy (Study III) 
The prevalence of periodontal pathogens at baseline and follow-up was assessed by PCR (Table 3).  
Based on statistical analyses, A. a. was found to be more prevalent in women with cardiovascular 
disease (OR 5.48, 95% CI 1.04 - 29.77; p<0.05). In both groups using stepwise logistic regression 
analyses the main explanatory factor in the model for the occurrence of P.g., P.i., T.f. and T.d. was 
the existence of deep periodontal pockets. 
 
 
 
 
Table 3.   
Positive PCR findings for periodontal bacteria in the women at baseline and two years later. 
(Pearson’s chi-square test). 
 
Bacterium * 
 
HT  
Baseline 
 
2-year follow-up 
Non-HT 
Baseline 
 
2-year follow-up 
A.a. 
P.g. 
P.i. 
P.n. 
T.f. 
T.d. 
1/95 (1.1%) 
20/95 (21.1%) 
33/95 (34.7%) 
58/95 (61.1%) 
44/95 (46.3%) 
27/95 (28.4%) 
4/95 (4.2%) 
9/95 (9.5%)* 
21/95 (22.1%) 
57/95 (60.0%) 
31/95 (32.6%) 
32/95 (33.7%) 
2/40 (5.0%) 
6/40 (15.0%) 
12/40 (30.0%) 
23/40 (57.5%) 
24/40 (60.0%) 
13/40 (32.5%) 
5/40 (12.5%) 
3/40 (7.5%) 
10/40 (25.0%) 
21/40 (52.5%) 
18/40 (45.0%) 
16/40 (40.0%) 
*A.a. = Aggregatibacter actinomycetemcomitans; P.g. = Porphyromonas gingivalis; 
P.i. = Prevotella intermedia; P.n. = Prevotella nigrescens; T.f. = Tannerella forsythia; 
T.d. = Treponema denticola 
*p<0.05 (baseline vs. follow-up)  
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6.4 Saliva and hormone therapy (Study IV) 
In the final study (Study IV) pair-wise saliva values were obtained from 106 HT users and 55 non-
HT users. No differences were seen in salivary flow rates between or within the groups. In the HT 
group a very low (<0.1 ml/min) unstimulated flow-rate was obtained in 5.6% (n=6) at the baseline 
and in 2.8% (n=3) at the two-year follow-up. Respective values for non-HT group were 5.8% (n=3) 
and 3.8% (n=2). For stimulated saliva flow rate the corresponding values were 0% and 0% for the 
HT group and 1.8% (n=1) and 0%, respectively. Positive yeast counts were observed in 61% (n=63) 
of HT users and in 60% (n=32) of non-users (Ns.), and at the follow-up the corresponding numbers 
were 37% (n=39) and 35% (n=19) (Ns.). Results of the salivary flow, buffer capacity and yeast tests 
are seen in Table 4. 
 
Salivary albumin, IgG and IgM concentrations decreased statistically significantly in the HT group 
during the two-year observation period. A one-way repeated measures ANOVA was conducted to 
compare levels of salivary flow rate, total protein, albumin, IgA, IgG and IgM levels at baseline and 
2-year follow-up. The means and standard deviations are presented in Table 4. There was a 
statistically significant effect for time for consecutive variables: The values were; for albumin: 
Wilks’Lambda=0.869, F(1, 94)=14.16, p=0.0003, partial eta squared=0.131, for IgG: 
Wilks’Lambda=0.947, F(1, 94)=5.235, p=0.0024, partial eta squared=0.053, and for IgM: Wilks’ 
Lambda=0.863, F(1, 94)=14.92, p=0.0002, partial eta squared=0.137. The logistic regression 
analysis showed that the only statistically significant explanatory factor for higher than median 
salivary albumin concentrations was the number of teeth of the subject. The other study parameters 
were not found to correlate with the salivary protein values.  
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Table 4.  
Baseline and follow-up (2 years) salivary flow rates, yeast counts, buffer capacity and biochemical 
constituents   [(Means ± SD or n (%)]. (Pearson’s chi-square test for class variables, and Student’s t 
test for continuous variables in cross-sectional study, and ANOVA for repeated measures for the 
prospective study). 
 
 HT (106) 
  
Non-HT 
(55) 
    
 
Baseline 2-year 
follow-up 
p-value Baseline 2-year 
follow-up 
p-value Significance 
between 
groups in 
baseline 
Significance 
between 
groups in 
follow-up 
Unstimulated 
salivary flow 
rate (ml/min) 
0.6 ± 0.4 0.7 ± 0.4 Ns. 0.6 ± 0.4 0.6 ± 0.4 Ns. Ns. Ns. 
Stimulated 
salivary flow 
rate (ml/min) 
2.0 ± 0.9 2.0 ± 0.8 Ns. 1.7 ± 0.8 1.8 ± 0.8 Ns. Ns. Ns. 
Positive yeast 
count  
63(61%) 32(60%) p<0.01 39(37%) 19(35%) p<0.01 Ns. Ns. 
Buffer 
capacity 
  Ns.   Ns. Ns. Ns. 
  High 85 (90%) 95(91%)   42 (86%) 45(87%)     
  Medium 7 (7%) 8 (8%)  6 (12%) 6 (12%)    
  Low 2 (2%) 1 (1%)  1 (2%) 1 (2%)    
Total protein 
(mg/ml) 
1.46 ± 0.5 1.47 ± 0.4 Ns. 1.53 ± 0.4 1.55 ± 0.4 Ns.  Ns. Ns. 
Albumin 
(µg/ml) 
306 ± 183 243 ± 115 p<0.001 311 ± 168 299 ± 222 Ns.  Ns. Ns. 
IgA (µg/ml) 26.0 ± 15.1 24.7 ± 12.8 Ns. 31.6 ± 16.9 32.6 ± 20.9 Ns.  Ns.  p<0.05 
IgG (µg/ml) 20.1 ± 15.8 17.1 ± 13.1 p<0.05 22.8 ± 20.3 20.4 ± 22.6 Ns.  Ns.  Ns.  
IgM (µg/ml) 1.51 ± 1.2  1.18 ± 1.1 p<0.001 1.93 ± 1.6 1.66 ± 1.6 Ns.  Ns.  p<0.05 
Ns.= not significant 
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7.  DISCUSSION 
 
7.1  Rationale for the study  
During menopause women go through biological changes, particularly in their secretion of female 
sex steroid hormones, with reduction in estrogen levels being especially pronounced (Brace & 
McCauley 1997). The transition to menopause can occur over a 10–15 year period (Morrison et al. 
2006).  As a variety of climacteric symptoms characterize the menopausal period, some women at 
this time live with expectations of worsening health (Matthews 1992). Many menopausal women 
also seem to suffer from oral discomfort (Meurman et al. 2009). 
 
Women using HT generally experience satisfactory relief of vasomotor symptoms, such as hot 
flushes, sweating, palpitation and/or sleeping problems, and also urogenital problems, such as 
vaginal dryness, itching, and dyspareunia (Notelovitz et al. 2000; MacLennan et al. 2001; Stearns et 
al. 2002; Rutanen & Ylikorkala 2004; Nelson 2008). However, women not only take HT to avoid 
climacteric symptoms, but also to protect themselves from cardiovascular diseases and 
osteoporosis, and also for increased well-being (Seeman et al. 1995; Herrington et al. 2000; Thunell 
et al. 2005; Jalava-Broman et al. 2008).  We did not ask in our questionnaire whether HT users had 
chosen to take HT to avoid climacteric symptoms or for some other reason. It is known that 
estrogens also influence oral health in a number of ways and saliva undergoes changes depending 
upon the levels and type of these hormones (Yalcin et al. 2005). In support of our study hypothesis 
there is no doubt that many women clearly benefit from the use of HT, which may also have effects 
in the oral cavity (Friedlander 2002; Rusanen & Ylikorkala 2004).  
 
Our hypothesis also rested on the idea that those women who had chosen to take HT in the first 
place were women with better health and health habits in general (Hemminki et al. 1993; Matthews 
et al. 1996).  As our study was carried out prior to the controversial reports from HERS and WHI on 
HT we consistently hypothesized that HT users would also have better oral health than those 
women who do not use HT. HT users had been characterized as well-educated, slim women who 
had never smoked (Egeland et al. 1988; Cauley et al. 1990; Topo et al. 1991). Therefore we 
logically thought that the oral health of HT users would be better than that of non-users. However, 
in the capital city area of Helsinki where the present study was conducted, demographic differences 
in employment, social class, or level of education did not exist between HT users and non users in 
previous studies (Topo et al. 1995).  
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When the results from large population studies and controlled trials were published after the onset 
of our present series of studies (Hulley et al. 1998; Herrington et al. 2000; Manson et al. 2003; Hsia 
et al. 2006) the number of users of HT decreased (Kase 2009).  Despite the fact that recent 
experimental and clinical studies have indicated that the effects of HT depend on the estrogen and 
progesterone/progestin formulation, dosage, mode of administration, patient's age, associated 
diseases, and duration of treatment (Harman 2006; Caufriez 2007) some women using HT have 
worries and fears concerning adverse reactions to HT which might affect decision making regarding 
its use (Tiihonen et al. 2007). However, our investigation on oral health and hormone treatment was 
carried out before the results from these randomized trials (HERS and WHI) were published.  
 
7.2 Evaluation of the methods 
For the present study we succeeded in collecting a representative sample of woman at the age of 
their climacterium. We did not analyse the effect of the use of HT on oral health, thus we compare 
the groups of women using HT or not using HT. This study was carried out from 1997 to 2001. At 
that time approximately 200,000 women, aged 45 or more, used HT in Finland (Rutanen & 
Ylikorkala 2004).  
  
In both studies questionnaires were used. Response rates according to the original study populations 
(Study I n=3176, and Studies II-IV n=400) are generally acceptable (65% in Study I and 62% 
(baseline) and 48% (follow-up) Studies II-IV). Comparable response rates (63%) were achieved in 
a Finnish questionnaire study on HT (Tiihonen et al. 2007) and (53%) in a study of self–medication 
for upper gastrointestinal symptoms (Sihvo & Hemminki 1997). For statistical analyses we had to 
exclude a few subjects who had changed their hormonal medication during the follow-up period. 
The exclusion did not have any effect on the final statistical results. The characteristics of the 
women who were dropped out from the final statistical analyses or who themselves discontinued for 
various reasons were analysed with respect to those who were followed-up using cross tables and t 
tests;  no significant differences were found. It was impossible to characterize the dental and oral 
health of the non-responders of our clinical study. We can only speculate that maybe the non-
responders were those with poor oral health and poor self-assessed oral and general health. This 
free-of-charge dental check-up was thought to be a good incentive to attend our study. However, in 
support of our hypothesis that women using HT are more interested in their health than non-users, 
more HT users responded at the baseline to our invitation to attend our study than non-users (138 
HT users vs. 100 non-users). 
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We did not include questions on social status or education in our questionnaire; however, it can be 
assumed that the large population cohorts originally included (n=3173) effectively leveled off bias 
in this regard. Using a questionnaire may cause difficulties in defining the actual prevalence of 
symptoms or poor dental habits: they may be even more common among populations than surveys 
indicate (Ahlberg 2008). We therefore conducted the clinical follow-up study to verify the 
prevalence of oral symptoms reported in the first questionnaires.  
 
A questionnaire was also used at the follow-up, and the subjects were informed of this in the 
invitation letter; therefore, more precise questions were able to be added to the questionnaire. 
Nevertheless, despite the request to check their current regular medication before attending the 
examination, a considerable number of women still did not remember all their medications when 
filling in the questionnaire. Therefore we had to categorize the medication fairly widely, especially 
concerning the use of neurological and psychiatric medications and also cardiovascular 
medications. To verify menopause is difficult by using a questionnaire. Thus our results are based 
on self-assessed menopausal stage. Use of any medication (nature of drugs) was not associated with 
oral health variables, however. 
 
7.3 Prevalence of oral symptoms and hormone therapy 
 
7.3.1 Sensation of PM and BMS  
We observed in our questionnaire study that the prevalence of PM was 8.2% of the total sample. 
There was no difference between users and non-users of HT in the prevalence of PM. In addition, 
there was no difference in incidences of use of other medications between those who had PM and 
those who did not have PM (data not shown).  According to logistic regression analyses, climacteric 
symptoms were found to be predictive of PM, and the use of HT increased the occurrence of PM. 
We thus concluded that PM seemed to be associated with climacteric symptoms in general and that 
the use of HT did not prevent the PM. However, there is nonetheless no certainty as to whether HT 
had given some relief from oral symptoms or not as this result was based only on questionnaire. It 
may also be that women with the most severe symptoms decided to use HT. 
 
At the clinical follow-up study, women received the questionnaire prior to the clinical examination. 
According to the questionnaires, PM was reported by 9.4% of the HT users at baseline and by 5.7% 
two years later. For the non-HT users, the corresponding numbers were 12.7% and 1.9%. However, 
after clinical evaluation of reported PM, among HT users a code of “6” (no reason found for 
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sensation of PM/BMS) was only found for in 4.7%, and at the follow-up for 2.8%. For the non-HT 
users, respective values were 7.2% at the baseline, and 0% at the follow-up.  As mentioned earlier, 
using a questionnaire may cause difficulties in defining actual prevalence: symptoms may be under- 
or over-estimated, as for the patient it is difficult to distinguish PM from any other organic disease 
in the oral cavity. This was also seen in our clinical evaluation of the cases of PM reported in 
questionnaire. 
 
Abnormal sensations in the oral cavity such as BMS present a difficult diagnosis for many 
clinicians. Diagnostic criteria are not consistent and the etiology of BMS is known to be 
multifactorial and poorly understood by dentists and physicians (Maltsman-Tseikhin et al. 2007; 
Abetz & Savage 2009). It seems likely that both physiological and psychological factors play a role 
in BMS, but the interaction between these and the relative significance of each remains largely 
speculative and remains an enigma (Abetz & Savage 2009). BMS mainly affects postmenopausal 
women and, because of this, it has been postulated that menopause, the cessation of menopause, or 
hormonal disruption is a precipitating factor. However, according to Abetz & Savage (2009) 
women with BMS do not have more hormonal abnormalities than those without.  
  
The prevalence of BMS has been estimated to be 0.7% - 4.5% in the general population (Basker et 
al. 1978; Locker & Grushka 1987; Lipton et al. 1993), although higher figures have been presented 
(Tammiala-Salonen et al. 1993). These prevalence values are similar to those in our study for PM 
without any clinically observable explanation. However, number of those cases in our study was 
very small, and we did not specify the burning sensation as it has been stated for BMS (Zakrewska 
et al. 2005), therefore we did not give any BMS diagnoses to our subjects. 
 
 
7.3.2 Sensation of dry mouth (xerostomia) 
In our questionnaire study DM was reported by 19.9% of subjects. The use of HT did not correlate 
with the occurrence of DM. However, 34% of those suffering from climacteric symptoms reported 
also having DM. The women with climacteric complaints or those who assessed their general health 
as bad had a significantly increased risk for the occurrence of DM (p=0.000).  
 
For the follow-up study, DM was complained by 28% at the baseline and by 24.3% at the two-year 
follow-up. There was no significant difference between the HT users and non-users in reporting 
DM. The selection of the covariates used in our studies may be criticized, as they did not adequately 
take into account all possible systemic and/or psychological factors. Nevertheless, the study was 
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planned to evaluate the occurrence of self-assessed symptoms and in regard of the use of HT. 
Another weakness was the drop-out of subjects which was done due to women changing their HT 
status during the 2 years of follow-up. They were then excluded from the statistical analyses.  
 
Nederfors et al. (1997) estimated the prevalence of xerostomia in their study to be 21% and 27% in 
men and women, respectively. Similarly, Bergdahl (2000) reported the prevalence of subjective oral 
dryness to be 22% among 20 to 69 year old men and women when asked by questionnaire. A 
questionnaire study on pre- and postmenopausal women at 53-54 years of age showed the 
prevalence of xerostomia to be 12.2% - 18%, irrespective of the use of HT (Jansson et al. 2003). 
Our results on DM and PM are based on self-assessed sensations and not on clinical examinations, 
therefore these results provide valuable information on self-assessed oral well-being of the women 
in this study cohort. 
 
7.4  Oral health parameters and hormone therapy 
According to the follow-up clinical study presented her, the dental health of the group of 
menopausal-aged women studied was fairly good. The relatively high mean DMFT index score is 
understandable as in the youth of these cohorts (born in 1940-1948) dental treatment in Finland 
comprised mainly extractions of the teeth or restorative treatment with large amalgam fillings. The 
number of teeth was higher than reported in Finnish national health survey (Kansanterveyslaitos 
2004), where the mean number of teeth was reported to be 21.5, and in women aged 55-64 years 
was 15.8. In our study mean number of teeth in both groups was over 23 with no differences 
between the groups or during follow-up.  
 
Until the year 2001, Finns born before 1956 had not been eligible for any nationwide subsidized 
dental care in adulthood. In Helsinki, for practical reasons, due to a shortage of oral health 
professionals, subsidized dental care covered only those born in 1963 and later until the year 2001. 
The women attending our study were all living in Helsinki at the time of the study. Therefore the 
majority of the study patients had used private dentists for their dental appointments instead of 
community health center clinics. As far as we know, there are no previously published data on the 
dental status of women of these age groups in general. The weakness of the study was the fairly 
short two-year follow-up period where big changes in oral health parameters are not to be expected. 
However, the periodontal conditions may alter within this time period if the treatment is 
appropriate. But to see changes in occurrence of dental caries, this two-year follow-up time is too 
short. It is well known that that caries is associated with reduced salivary flow (Nauntofte et al. 
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2003), and dramatic increase in caries activity is mainly seen in individuals with no or very low 
saliva flow rate for example in individuals taking medication with hyposalivation as a side effect, 
and in patients with Sjögren´s syndrome (Atkinson & Fox 1992; Ravald & List 1998). In our study 
the salivary flow rates were normal, and only a few very low salivary flow rates measured 
measured, therefore no dramatic change in caries were expected to occur. In contrast to our results 
Yalcin et al. (2006) found in their two-year follow up study of 348 women (aged 44-65) that the 
women using HT had lower DMFT, DMFS and CPI values than non-users. For practical reasons we 
used only DMFT-index in our study to describe the dental status. However, DMFS-score which 
count the number of surfaces which are decayed (D), missing (M), and filled (F), would have given 
a more precise picture of the current dental status, and probably shown more differences between 
groups than use of DMFT did (Manji & Fejerskov 1994). When using DMFS or DMFT, it is 
recommended that the M-score is excluded when reporting affected surfaces, and therefore we 
measured DT and FT separately. 
 
However, according to the measured CPITN results, there was a high prevalence of periodontitis in 
our study cohort. Although the reliability of CPITN in diagnosing periodontal disease may be 
criticized, it is a practical tool for population studies (Unell et al. 2000). The index was originally 
developed for the purpose of assessing periodontal treatment needs in a population (Ainamo et al. 
1982; Ainamo & Ainamo 1994), but it has been recommended for prevalence studies and 
assessments of the severity of periodontal disease (Cutress et al. 1987). In the present study the 
number of 6 mm deep gingival pockets was included in the statistical analyses, which gave more 
precise information on the severity of periodontal disease. According to a large Finnish national 
health survey, the prevalence of periodontitis measured by CPITN among 45 to 64 year old women 
was 62% (Kansanterveyslaitos 2004). Periodontitis was diagnosed when at least one pocket was 
measured to be ≥ 4mm (CPITN of score 3). In our study 79% of HT users at baseline and in 71% at 
the follow-up had CPITN scored of 3 or more. The values for non-HT users were 80% vs. 76%, 
respectively. The CPITN method for evaluating periodontitis has been criticized for overestimating 
periodontitis in young and healthy subjects and underestimating it in elderly subjects (Gaengler et 
al. 1988; Baelum et al. 1993). 
  
Severe periodontits (CPITN score of 4) is diagnosed when there are at least one gingival pocket ≥ 
6mm deep. In Finnish national health survey (Kansanterveyslaitos 2004) the prevalence of severe 
periodontitis was 17% in the 45-54 year old age group, and 23% in the 55-64 year old age group. 
To define the severity of periodontal status in our study, we recorded the numbers of ≥ 6 mm deep 
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periodontal pockets separately. The mean numbers of ≥ 6 mm deep periodontal pockets were 0.9 ± 
1.7 at baseline vs. 1.1 ± 2.1 two years later in the HT group, and in non-HT group 1.0 ± 1.7 vs. 1.2 
± 1.9, respectively. These results indicate that in our study cohort the prevalence of severe 
periodontitis was lower than reported in the Finnish national health survey. 
 
As definitions of periodontal disease in epidemiologic studies lack uniformity the findings from 
different research groups are not always readily interpretable (Borrell & Papapanou 2005). Recently 
a review was published by König et al. (2010) on periodontal health in Europe. According to the 
review CPITN was assessed in most studies (König et al. 2010), although the limitations of this 
widely used index are well recognized (Savage et al. 2009). In our study for practical reasons the 
protocol had to be restricted according to periodontal status measuring, and therefore the use of 
CPITN was most convenient for us. 
 
However, contrary to the expectations based on our study hypothesis, there was no difference in 
dental or periodontal health between women using HT or not using HT.  
 
Every fifth women in our cohort was a current smoker. Smoking is known to be a major risk factor 
for periodontitis, affecting the prevalence, extent, and severity of periodontal disease (Novak & 
Novak 2006). There was no difference in the number of smokers on a percentage basis between HT 
users and non-user groups, both in the questionnaire and in the follow-up study. According to our 
logistic regression analyses in questionnaire study (Study I), smoking was a significant risk factor 
for DM. Smoking was also used as one covariate in logistic model when investigating risk factors 
for higher than median salivary protein values (Study IV). Regarding periodontal status and 
smoking, our data is not sufficient to allow us to make statistical conclusions. 
 
Based on present knowledge of periodontal diseases and mechanism of tissue destruction, the role 
of matrix metalloproteinases (MMP) are known to play a significant role in the regulation of 
cellular communication and immune functions by processing bioactive molecules, including 
cytokines, hormones and growth factors (Sorsa et al. 2004). MMPs are involved in physiological 
processes during tissue development, remodeling, and wound healing (Uitto et al. 2003; Sorsa et al. 
2006). MMP-8 is one of the central biomarkers in the connective tissue breakdown of periodontitis 
(Sorsa et al. 2004; Sorsa et al. 2006). MMP-8 levels detected by immunofluorometric assay (IMFA) 
in GCF have shown to be a good aid in diagnosing periodontal disease (Mäntylä et al. 2003; 
Mäntylä et al. 2006). Salivary MMP-8 has also been detected by IMFA (Gursoy et al. 2010). There 
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is no doubt that the lack of the information on MMP-8 levels is a weakness on our results 
concerning the periodontal status of the studied women. 
 
7.5 Periodontal microbiota and hormone therapy 
If the subject is healthy, oral microbiota do not pose a systemic threat. Dental and/or oral mucosal 
diseases can lead to bacteraemia of oral origin, however (Meurman et al. 2009). Anatomically, the 
oral cavity is the only part of the human body where hard tissues directly penetrate soft tissue 
epithelium: teeth surrounded by the gingival epithelium and periodontal connective tissue extend 
from alveolar bone to the oral cavity and may open the parenteral space to the outer environment. 
Even chronic low-grade exposure to bacteria of oral origin may then have systemic consequences, 
including cardiovascular diseases. In this context the association between periodontal disease and 
atherosclerotic diseases has been much discussed in literature (for reviews, see: Meurman et al. 
(2004) and Pussinen & Mattila (2004). Pussinen et al. (2007) suggested that systemic exposure to 
P.g. may predispose to incident stroke. The progression of atherosclerosis is also modified by 
female sex hormones (Collins et al. 2007). Therefore the role of oral microbiota is also of interest in 
further studies.  
 
Sex hormones have long been considered to play an influential role in periodontal tissues and 
periodontal disease progression (Sooriyamoorthy & Gower 1989; Mascarenhas et al. 2003; Brennan 
et al. 2007; Carillo-de-Albornoz et al. 2010). However, there are hardly any data on the effect of 
female sex hormones on oral microbiota in menopausal or postmenopausal women. There are more 
data on the effects of oral contraceptives and pregnancy on oral micro-organisms (Jensen et al. 
1981; Klinger et al. 1998; Raber-Durlacher et al. 1994; Laine 2002). 
 
Our Study III was based into on the known associations between periodontal bacteria and systemic 
diseases (Meurman et al. 2004) and the interactions between HT use and general health (Manson et 
al. 2003). We thought that HT might affect periodontal infections, as reflected in the occurrence of 
specific bacteria. We thus assumed consistently that the more health-conscious HT users would less 
frequently harbour periodontal pathogens when compared with non-users at the end of this two-year 
study. 
 
However, in our clinical study the strongest explanatory factor for harbouring the periodontal 
bacteria investigated was the existence of deep periodontal pockets in both the HT and non-HT 
groups. This result as such came as no surprise since deep periodontal pockets and furcation 
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involvement are obviously the characteristic sites harboring periodontal pathogens. Also, self-
assessed poor oral health status showed an association with harbouring of the bacteria investigated.  
However, only the less harmful P.n. species, which are mainly associated with gingivitis (Lee et al. 
2006), were statistically linked with self-assessed poor oral health. P.n. is also frequently isolated 
from periodontally healthy sites, like the P.i. species (Paster et al. 2001). Since we used pooled 
plaque samples, there are no data from individual periodontal pockets. Our aim was to assess the 
overall association of the HT use and periodontal microbiota rather than monitor single pockets in 
this respect. In our study in regards the effect of reported systemic diseases on the studied 
microbiological results, A.a. was found to be more prevalent in women with cardiovascular disease.  
No other bacterial species was associated statistically with any other systemic disease reported 
(asthma or rheumatic diseases). However, in general the number of these cases was only a few 
individuals, so the finding on A.a. probably has no clinical relevance. 
 
7.6 Salivary analysis and hormone therapy 
HT has been reported to ameliorate dry mouth sensations, which are very common in elderly 
women (Hakeberg et al. 1997; Leimola-Virtanen et al. 1997a; Wardrop et al. 1989; Friedlander et 
al. 2002; Eliasson et al. 2003).  The salivary flow rate has been shown to decrease during the 
menopausal period (women of age 50.7 years compared to non-menopausal women at an age of 
42.4 years) but to increase after the start of HT with alendronate and calcium supplementation in 
younger postmenopausal women (Yalcin et al. 2005). The authors concluded that this was the effect 
of HT, but they did not study the effects of alendronate separately (Yalcin et al. 2005). However, in 
a study on the effects of alendronate and HT on elderly women, there was a significant decrease in 
the mean unstimulated salivary flow in the alendronate group, which of course was not a desirable 
result from the clinical point of view (Eviö et al. 2006).  
 
According to standardized methods for saliva flow rate measurement it has been shown that 
unstimulated saliva tests should be perfomed at fixed time-points or over limited time interval early 
in the morning (Flink et al. 2005) in order to obtain reliable results (Tenovuo & Lagerlöf 1994).  In 
our present study, the study subjects were given to clinical examinations at varying times. Although 
they were asked to avoid eating, drinking and smoking two hours prior to the appointment time, we 
could not avoid stimulus effects prior to those two hours that day. This uncontrolled time of salivary 
flow measurement and collection undoubtedly caused higher values to be obtained for unstimulated 
flow rates and to some extent also for paraffin stimulated saliva flow rates.  
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No differences were observed in measured unstimulated and stimulated saliva flow rates between 
HT users and non-users, and between the baseline and follow-up study. However, we measured 
clearly higher paraffin stimulated whole saliva flow rate values than reported earlier in healthy 
women (Heintze et al. 1983; Sevón et al. 2008) and also higher unstimulated flow rates than 
reported earlier (Heintze et al. 1983; Yeh et al. 1998). These high stimulated flow rates may also 
explain the high frequency of “high” buffer capacities that we found. Stimulation is known to affect 
the carbonic acid/bicarbonic acid system in saliva (Bardow et al. 2000). Unfortunately we did not 
measure the pH of the unstimulated or stimulated saliva, which would have given us more 
information on the saliva collected than using only a dip-slide test on stimulated saliva.  
 
The frequency of positive yeast counts in the saliva of our study patients at baseline was also higher 
than reported previously for “normal“ people (Odds 1988).  However, at follow-up, the frequency 
of positive yeast counts was lower in both groups, being 35% of HT users and 37% of non-users, 
which are normal prevalences (Odds 1988). An explanation for such a clear drop in the frequency 
of positive yeast counts in both groups is that after the baseline study, dip slide test scores of  3 
(indicating a high yeast count;  more than 50 CFU) were reported to the patients. Therefore most of 
those with high dip-slide scores had been treated for their high yeast colonization before the follow-
up study testing. We did not define the role of removable dentures on positive yeast counts although 
the presence of dentures is a known risk factor for yeast colonization. This is of course an error in 
this study. 
 
In our study a statistically significant decrease was seen in the mean salivary IgG, IgM and albumin 
values of the HT users while no such effect was seen among the non-users. These findings may 
reflect an improvement in mucosal integrity among the HT users, since albumin, IgG and IgM in 
saliva have been suggested to be serum ultrafiltrates to the mouth and, consequently, their decreased 
concentrations may indicate improved mucosal and gingival health in the oral cavity (Meurman et 
al. 2002, Aviv et al. 2009). However, according to present knowledge, salivary IgG and IgM are 
primarily derived from GCF or as serum infiltrate (Kaufman & Lamster 2000; Van Nieuw et al. 
2004). In our logistic model the only explanatory factor for higher than median salivary albumin 
concentrations was the number of teeth of the subject. This supports the GCF origin of albumin. In 
both groups of the present study the other protein concentrations analysed stayed at the same level 
during the 2-year follow-up but IgA and IgM values were significantly higher in the non-HT group. 
However, as pointed earlier, we found quite high stimulated salivary flow rates, and they may also 
partly explain the immunoglobulin and albumin results in the HT group. The clinical relevance of 
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these results needs to be assessed in future studies. In addition, we did our analyses only on whole 
saliva sample whereas the minor salivary gland secretions have been shown to be rich in IgA (Shiba 
et al. 1980). 
 
In the study by Johnson (2005) in African-American postmenopausal women, salivary IgA 
concentrations were significantly higher than in Caucasian women, thus suggesting racial 
differences in this parameter. In the present series of studies all the women were Caucasian, which 
is strength of these results. Also, the Finnish population is racially homogenous. However, in 
contrast to our results, salivary immunoglobulin concentrations were found to decrease 5 months 
after starting HT while salivary peroxidase and total protein output increased in the longitudinal 
study by Leimola-Virtanen et al. (1997b). It must be kept in mind that we did not measure the effect 
of estrogen treatment nor did take into account the type of hormone therapy used (ie. ET, EPT, PT).  
 
Natural variation in saliva parameters in general has to be taken into account when interpreting 
results on saliva constituents (Dawes 1987); this particularly needs to be emphasized in salivary 
hormone assessments (Ostrowska et al. 2001; Chatterton et al. 2005; Tivis et al. 2005). However, 
Patacchioli et al. (2006) observed in their study on stress reactions analysed by repeated salivary 
cortisol measurements that menopause was not associated with an impairment of circadian 
fluctuations of the cortisol concentrations. In the present investigation we did not analyse any 
hormone concentrations, however. It is also worth mentioning the need of standardizing the 
collection of saliva, as shown by Laine et al. (1999). They observed in a group of menopausal 
women that repeated collection resulted in significantly increased flow rates over seven weeks of 
observation. In our study, the interval time between the collections was two years, so it is 
improbable that there was any effect in this regard.  
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8. CONCLUSIONS 
 
In general, the present findings showed that 50 to 58 year old women living in Helsinki have fairly 
good oral and dental health. These observations are partly explained by the fact that life expectancy 
has increased and also the number of dentate people is increasing. Today the standard of dental 
treatment allows people to retain their own teeth but it seems that many periodontal problems still 
occur.  
 
Prevalence numbers for sensation of PM and DM reported in the questionnaires of the present study 
were in consistent with previously published data on the prevalence of these symptoms. However, 
clinical examination clarified that some PM symptoms were caused by treatable factors. 
Interestingly, our results in Study I showed that the occurrence of PM and DM seemed to be 
associated with climacteric symptoms in general, but the use of HT did not reduce the prevalence of 
oral symptoms studied. This was in contrast to our original study hypothesis. 
Further studies with longer follow-up time are needed to evaluate the effect of HT on oral health 
parameters. The role of HT in ameliorating oral symptoms is still controversial. It seems that the 
effect of HT is highly individual so that some women with menopause-related symptoms benefit 
from HT while others do not. It is also probable that different hormone preparations have different 
effects in this regard.  However, so far there are no randomized controlled studies to answer these 
questions.  
Although not a population study still the present study gives new information about the correlation 
of the use of HT with oral symptoms in women of menopausal age living in Helsinki, Finland. 
When planning optimal HT for menopausal women, oral symptoms are a factor that may be 
considered by the patient and her gynecologist. 
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9. SUMMARY 
 
Based on results of the present series of studies the following conclusions can be drawn: 
 
 
1. A sensation of PM was reported by 8.2% and 19.9% complained of a sensation of DM, 
(xerostomia). The occurrence of PM and DM seemed to be associated with climacteric symptoms in 
general. Use of HT did not have any effect on this association. Poor self-assessed general health 
increased the risk for PM and DM (Study I). 
 
2. Dental health, according to the DMFT index, did not differ between the HT users and non-
users during the two-year follow-up time. However, during the follow-up, filled teeth index 
increased in the HT group (p<0.05), which may indicate a more health-conscious attitude in this 
group.  Self-assessed oral health was considered satisfactory by 61% of HT users at baseline and by 
59% at the follow up, for non-users respective values were 51% vs. 56%. These differences were 
not statistically significant (Study II). 
 
3. The use of HT did not correlate with periodontal conditions based on the clinical 
examinations. Periodontitis was defined as at least one sextant had a CPITN score of 3.  In HT 
group periodontitis was diagnosed at baseline in 79% and at two-year follow-up in 71%. The 
respective figures for non-HT users were 80% and 76%. Mean number of ≥ 6 mm deep periodontal 
pockets were 0.9 ± 1.7 at baseline vs. 1.1 ± 2.1 two years later in the HT group, and 1.0 ± 1.7 vs. 
1.2 ± 1.9, respectively, in the non-HT group. These results concerning periodontal status indicate a 
higher prevalence of periodontitis but lower prevalence of severe periodontitis than reported in the 
Finnish national health survey in adults of this age group.  
 
According to microbiological PCR evaluations of periodontopathogens, P.g. decreased in the HT 
group during the follow-up (p<0.05). Further studies are needed to determine the clinical relevance 
of this result. At baseline, positive yeast counts in the saliva of our study patients were higher than 
reported earlier in normal healthy population. The patients were informed when their yeast values 
were high. At follow-up, the frequency of positive yeast counts was at normal levels (Study III). 
.  
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4. During the two-year follow-up time the salivary albumin, IgG and IgM concentrations 
decreased slightly in HT users. This may indicate improvement in soft tissue integrity. However, 
more specific methods are needed to evaluate changes in oral mucosa and gingiva. There was no 
difference between the salivary flow rates in HT users and non-users (Study IV). 
 
 In general, the present findings showed that 50 to 58 year old women living in Helsinki, Finland, 
have fairly good oral and dental health, and they were interested in their oral health. In contrast to 
our study hypothesis, in our present study cohort there was no difference in the studied oral and 
dental health parameters between the women using HT and not using HT.   
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